3-Dimensional Pharmaceuticals, Inc.. The Group's principal activity is the discovery and the development of drugs, an integrated set of proprietary technology called DiscoverWorks. This technology accelerates and improves the drug discovery process and enables the scientists to design characteristics into drug candidates that increase the probability of development success. The Group has a pipeline of drug candidates in the areas of cancer, inflammation, metabolic and cardiovascular diseases. Discovers and develops drugs, an integrated set of proprietary technologies called DiscoverWorks

Able Laboratories, Inc.. The Company's principal activity is to develop, manufacture and sell generic drug products. Generic drugs are the chemical and therapeutic equivalents of brand-name drugs. The Company manufactures and markets prescription generic drugs including tablets, capsules, suppositories and liquids. It manufactures and sells a broad range of prescription pharmaceutical products in solid oral dosage and suppository forms. It is working on adding liquid dosage forms to its product line. The products of the Group are marketed under the brand names include: Esgic Plus(R), Soma(R),

Acadia Pharmaceuticals, Inc.. The Group's principal activity is discovers, develops and commercialization of small molecule drugs for the treatment of central nervous system disorders. It currently has five programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs and major commercial markets. The four Phase II-stage clinical programs, for which it has retained worldwide commercialization rights, are ACP-103 for treatment-induced dysfunctions in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia, ACP-1

Actavis Group HF Formerly known as Pharmaco HF. The Group's main activities are the production and distribution of generic pharmaceutical products, ranging from tablets and capsules, injectables, infusions, suppositories, suspensions, creams and ointments. The Group operates worldwide through its own brand names and also packages and sells under third party's subsidiaries. Its primary markets are Germany, Turkey, Bulgaria, Serbia, Russia and Scandinavia. The Group owns production plants in Iceland, Turkey, Bulgaria, Malta and Serbia. In 2005 the Group acquired eight companies: Biovena Pharma S

Acura Pharmaceuticals, Inc. Formerly known as Halsey Drug Co., Inc.. The Group's principal activity is the development, manufacture, sale and distribution of generic finished dosage pharmaceutical products and activepharmaceutical ingredients. It also conducts research, develops and manufactures proprietary, high-yield, short cycle time, environmentally sensitive opioid synthesis processes intended for use in the commercial production of certain bulk opioid active pharmaceutical ingredients. The Group's Aversion TM Technology is intended for use in orally administered opioid-containing pharmac

Adcock-Ingram Limited. Adcock-Ingram Limited, first listed on the Johannesburg Stock Exchange in 1949, develops, manufactures and distributes over the counter medicines, branded prescription pharmaceuticals and generics, critical care hospital products and consumer personal care toiletry & household products. The group is also active in the vision care market, providing prescription lenses, spectacle frames and ophthalmic instruments. The group merged on 1st May 1996 with The Premier Pharmaceutical Company Ltd (Prempharm). Fiscal 1997 is the first full year's reporting on the new merged entity

Adeza Biomedical Corporation. The Company's principal activities are to design, develop, manufacture and market innovative products for women's health. Its initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm birth and assess infertility. The Company's principal product is a patented diagnostic test FullTerm, The Fetal Fibronectin Test, that utilizes a single-use, disposable cassette and is analyzed on its patented instrument, the TLiIQ System. It also markets and sells the E-tegrity(R) Test, an infertility-related test to access receptivity of the

Advanced Nutraceuticals, Inc.. The Group's Principal Activity is to Manufacture Nutraceutical And Pharmaceutical Products. The Manufacturing Operations Consist of Formulation, Manufacturing, Coating And Packaging of Encapsulated And Compressed Tablets And

Aeolus Pharmaceuticals, Inc. Formerly known as Incara Pharmaceuticals, Inc.. The Group's principal activities are to develop a series of catalytic antioxidant molecules which protect against the damaging effects of reactive oxygen derived molecules. The Group's target application will be the use of catalytic antioxidants to limit the side effects from damage caused by free radicals occurring in cancer radiation therapy. Free radicals, such as superoxide and peroxynitrite, cause damage in a broad group of diseases and conditions. Develops catalytic antioxidant molecules which protect against th

ENGAGED IN THE RESEARCH, DEVELOPMENT, MANUFACTURE AND MARKETING OF HUMAN AND ANIMAL DIAGNOSTIC TESTS AND TECHNOLOGIES

AGEN Limited is a biotechnology company specialising in the development and commercialisation of products to be used under professional supervision in the diagnosis of human and veterinary pathology. Efforts are largely directed at designing rapid blood tests for medical conditions related to human cardiovascular disorders and infectious disease diagnosis in humans and companion animals. AGEN's key markets in the Asia/Pacific Region, Europe and the Americas are served from Australia and regional offices in Switzerland and in the United States of America.

A H Robins Company, Incorporated.

Algos Pharmaceuticals Corporation. The principal activity of the Company is the development of a new class of proprietary drugs for managing pain which combine existing analgesics with N-methyl-D-aspartate receptor antagonist drugs and dextromethorphan that have been approved for human use in other applications.

Allergan Specialty Therapeutics, Inc. a development stage company, conducts research and development of potential human pharmaceutical products and commercializes such products through licensing. The company's research and development is focused on various pharmaceutical products such as tazarotene for the treatment of cancer, acne and psoriasis, memantine, a treatment to be used to halt the progression of optic nerve damage and AGN 194310 for the topical treatment of psoriasis. Tazaroptene is currently marketed under the brand name "Tazorac(R)" in the United States and "Zorac(R)" outside the

Alltracel Pharmaceuticals PLC. The Group's principal activities are the research, development and commercialisation of a portfolio of pharmaceutical and medical device patents, both granted and pending. The basic element of the platform technology, from which most of the patents are derived, (m.doc Active Technology) is a means to produce a desirable spectrum of bio-compatible compounds with differing structural and/or pharmacological properties in a single inexpensive chemical process. Researches, develops and commercialises a portfolio of pharmaceutical and medical device patents, both grant

Alpha 1 Biomedicals, Inc. is engaged in the development of pharmaceutical products for the treatment of diseases or conditions that arise as a result of immune system disorders. The company's research and development program is currently evaluating the Thymosin beta 4 as a treatment for cystic fibrosis and possible other diseases or conditions. It is also a partner in a project to develop certain treatments for the AIDS virus.

Alpha-Beta Technology, Inc discovers, develops and commercialize novel carbohydrate based products for the prevention and treatment of infectious diseases. The company currently is in the developing stage and devoting its activities towards research and development, marketing products under development, clinical trials and manufacturing. All of the company's revenue for the year are from interest received and other services. The major products of the company under development are betafectin (R), and PGG-glucan a carbohydrate product.

ALPharma Incorporated.. The Group's principal activities are to develop, manufacture and market pharmaceutical products for humans and animals. It manufactures and markets animal health products in over 80 formulations and dosage forms. The Group operates in three segments. Pharmaceuticals, prescription pain medicine in a capsule dosage form under the trademark Kadian. Active Pharmaceutical Ingredients develops, manufactures and markets a range of antibiotic fermentation based active pharmaceutical ingredients that are used, primarily by third parties, in the manufacture of finished dose pharm

American Biogenetic Sciences, Inc.. The Group's principal activity is the research and development of cardiovascular and neurobiology products for commercial development. The Group's research efforts have been focused on the development of products to diagnose, prevent and treat diseases in humans. The products of the Group are designed for in vitro and in vivo diagnostic procedures and therapeutic drugs. The Group's products include Thrombus Precursor Protein Diagnostic Test (TpP(TM)), Functional Intact Fibrinogen Diagnostic Test (FiF(R)), Antigen-Free Technology, Therapeutic Neurocompounds a

American Cyanamid Company is a research based life sciences company which discovers and develops medical and agricultural products and manufactures and markets them throughout the world. The company's products are produced or marketed in approximately 135 countries throughout the world. In December 1993, Cyanamid completed the spin off of Cytec Industries, the company's chemical business. Medical products accounted for 67% of 1993 revenues and agricultural products, 33%.

Amersham PLC Formerly known as Nycomed Amersham PLC. The Group's principal activities are the development, manufacture and sale of specialised products for research-based biotechnology supply and for the diagnosis and treatment of disease. The Group's business is carried out through two divisions. Amersham Health, provides diagnostic and predictive imaging products and services and related therapeutic products that focuses on cardiology, neurology and cancer. Amersham Biosciences, develops and provides integrated systems and solutions for disease research, drug development and manufacture. The

Amersin Life Sciences Corporation Formerly known as Hubei Pharmaceutical Group Ltd.. The Company currently has no operating business or interest in any subsidiary operations. During 2005, Company has discontinued its pharmaceutical divisions. The Company currently has no operating business or interest in any subsidiary operations.

Amgen Inc.. The Group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. The Group markets human therapeutic products in the areas of hematology, oncology, and inflammation. The Group's key products include EPOGEN(R), Aranesp(R), Neulasta(R), NEUPOGEN(R), and ENBREL(R). EPOGEN(R) and Aranesp(R) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white

Anergen, Inc. discovers and develops biopharmaceutical compounds for the treatment of autoimmune diseases. The company's products can treat a broad range of autoimmune diseases without suppressing the immune system. The company's research and development has two core technologies, AnergiX and AnervaX. AnergiX destroys or inactivates the T cells in the disease process. AnervaX stimulates the immune system to produce antibodies that may interfere with presentation of self-antigens to destructive T cells. The products currently needs significant research, laboratory testing and clinical trials.

Anesta Corporation. The principal activities of the Company are the research, development and commercialization of pharmaceutical products for oral transmucosal drug administration using its proprietary oral transmucosal system (OTS) for drug delivery.

Anhui Fengyuan Pharmaceutical. The Company's Principal Activities Are The Research, Development, Manufacture And Distribution of Chemical Compound Medicines, Biological Pharmaceutical And Chinese Medicine And Related Medicinal Preparations. Products Inclu

Anormed Inc.. The Company's Principal Activity is to Discover And Develop New Therapeutic Products For The Treatment of Variety of Diseases, Including Cancer, Hiv And Inflammation. The Company Also Discovers Diagnostic Applications of Medical Imaging of C

AP Pharma, Inc.. The Group's principal activity is to develop patented polymer-based delivery systems that enhance the safety and effectiveness of pharmaceutical compounds. These delivery systems are targeted at pain management, inflammation, oncology and ophthalmology applications. The Group is in process of the development of bioerodible injectable and implantable systems under the trade names Biochronomer(TM) and Bioerodimer(TM). The projects are under feasibility study and will require marketing clearance from the FDA before they can be sold in the United States. The Group has already deve

Applied Neurosolutions, Inc. Formerly known as Hemoxymed, Inc.. The Group's principal activity is to conduct research and development aimed at improving tissue oxygenation by increasing oxygen release from hemoglobin to provide therapeutic value to patients with serious, although unmet or underserved, medical needs. The Group is a development Stage Company. In 2004 The Group dissolved Its two subsidiaries, Molecular Geriatrics Corporation and Hemoxymed Europe SAS. Conducts research and development aimed at improving tissue oxygenation

Appligene Oncor specialises in the design, production and distribution of reacting substances and instruments for laboratory research in molecular biology. Reactive substances include specific enzymes, products from chemistry and fragments of DNA. The medical instruments are designed in order to aid the study of genes. There is quite a distinction between Appligene products and Oncor products. In general the Appligene products are destined for the general study of all living matters, whereas the Oncor products are more specific, such as those involved in the study of human genes and molecular

Ark Therapeutics PLC. The Group's principal activity is discovering, developing and commercialising products in areas of specialise medicine with particular focus on vascular disease and cancer. The Group product brands include Cerepro, Vitor, Trinam and Kerraboot. The Group's product in development focuses on the treatment for the fat metabolism problem associated with the most common therapy for HIV positive patients. The Group is also in the development of a diagnostic kit for cardiovascular risk, measuring oxidised LDL antibodies and a bio-degradable device placed around the outside of blo

Ascent Pediatrics, Inc. (formerly known as Ascent Pharmaceuticals, Inc.) is a drug developing company, developing drugs exclusively for the pediatric market. The products are designed to improve upon currently available products for common pediatric illness by applying the company's drug delivery and reformulation technologies. Ascent Pediatrics has four principal products in various stages of development namely: Primsol trimethoprim solution; Orapred syrup; Feverall and Pediavent albuterol. The company became publicly held in May 1997.

Astra AB is a world leader in the research, manufacturing and marketing of agents for gastrointestinal and respiratory diseases, cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. In the gastrointestinal product group, the antipeptic ulcer drug Losec is the dominant product. The product is approved in about 100 countries for short-term therapy and in some 40 countries for long-term therapy. Astra AB's two largest products in the cardiovascular product group are the beta-blocker Seloken and the vasodilator Plendil. Both products are used primarily

Astra AB is a world leader in the research, manufacturing and marketing of agents for gastrointestinal and respiratory diseases, cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. In the gastrointestinal product group, the antipeptic ulcer drug Losec is the dominant product. The product is approved in about 100 countries for short-term therapy and in some 40 countries for long-term therapy. Astra AB's two largest products in the cardiovascular product group are the beta-blocker Seloken and the vasodilator Plendil. Both products are used primarily

Astrazeneca Pharma India Ltd. The Company's principal activity is to research, develop and market medicines for serious health conditions. The Company provides products for six areas of health care: gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The Company sells its products in over 100 countries, manufactures in 20 and has major research centres in 7 countries. It's Research and Development is based in Sweden, the United Kingdom, the United States of America, Canada, France, India and Japan. Researches, develops and markets medicines for serious health co

Astrazeneca Plc. The Group's Principal Activities Are The Research, Development And Marketing of Medicines For Serious Health Conditions. The Group Focused on Seven Important Areas of Healthcare Such as Gastrointestinal, Cardiovascular, Oncology, Respirat

Atmospheric Glow Technologies, Inc.. The Group's principal activity is to develop Conducts research and development contracts related to possible applications of the patented OAUGDP(R) for the One Atmosphere Uniform Glow Discharge Plasma, a process of non-thermal, atmospheric pressure processing for use in areas such as sterilization, decontamination, surface cleaning and etching. The Group's technology is a simple, lower cost plasma generation technique. Atmospheric Plasma is created by electrically energizing air at standard atmospheric pressure and ambient temperature generating highly reac

Aurobindo Pharma Ltd. The Group's principal activities are to develop, manufacture and market active pharmaceutical ingredients, intermediates and generic formulations. The Group has its operations in India, Thailand, the United States, Hongkong, Brazil and China. During the year the Group acquired Milpharm Limited. Develops, manufactures and markets active pharmaceutical ingredients, intermediates and generic formulations

Aventis SA. The Company's principal activity is the provision of products and services for health and nutrition. The main divisions are Prescribed medicines, human vaccines and other activities. The Company has sold non-core businesses and sections of business during the past three years: Aventis CropScience, Aventis Animal Nutrition and the Therapeutical Proteins activities of Aventis Behring.

Axcan Pharma Inc. The Group's Principal Activities Are to Develop, Manufacture, Market And Distribute Gastroenterology Products And Therapeutic Treatments Primarily in North America And The European Union. The Products of The Group Are Used in The Treatme

Axis Biochemicals ASA is a clinical diagnostics company with products and technologies for chemical analysis of blood samples. The company focuses on alocohol related diagnostics, cardiovascular diagnostics and point of care diagnostics. In 1998 the company continued developing the three main areas: %CDT for diagnosing long term high alcohol consumption, Glycohemoglobin for follow up of diabetes patients and Homocysteine for diagnosing anaemia and cardiovascular diseases. The company has a major research and development activity in its laboratories in Bodo and Oslo in Norway. The company estab

B.M.P. Pharma Trading AG. The principal activity of the Company is the trading of pharmaceutical raw materials and nutracentical products. Furthermore the Company delivers raw materials to the pharmaceutical, health food and nutracentical industries. The Company was founded in 1979 by Bernd-Michael Joerss.

Basilea Pharmaceuticals. The Group's principal activity is to discover and develop innovative drugs for the treatment of bacterial infections, fungal infections and skin diseases associated with high unmet medical needs. The Group focuses on antibacterial, antifungal and dermatological markets. Discovers and develops innovative drugs for the treatment of bacterial infections, fungal infections and skin diseases

Offering Bayer consumer products and supplies.

1988 REVENUES WERE DERIVED FROM PRESCRIPTION & OVER THE COUNTER MEDICINES, 45% & COSMETICS & OTHER CONSUMER PRODUCTS 55%

Beihai Gofar Marine Biological Industry. The Group's Principal Activities Are The Manufacture And Sale of Pearl Pharmaceutical Products. Other Activities Include Production And Distribution of Marine Bio-Agricultural Medicine, Manufacture of Jewellery And

Beijing Double-Crane Pharmaceutical Company Limited. The Group's Principal Activities Are The Processing And Production of Raw Material Medicines. Other Activities Include The Processing And Production of Injection, Tablet, Capsule, Pellet And Pharmaceuti

Beijing SL Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Research, Development And Production of Medicine, Biochemical And Chemical Medicine.

Benzon, Alfred A/S. .

Bigmar, Inc.. The Group's principal activity is to manufacture and market generic pharmaceutical Oncology products and intravenous infusion solutions. It operates through three wholly owned subsidiaries: Bioren SA (Bioren), Bigmar Pharmaceuticals SA (Pharmaceuticals) and Bigmar Therapeutics (Therapeutics). Bioren manufactures and markets 22 types of intravenous infusion solutions and other related products. Pharmaceuticals segment manufactures and markets Oncology Products including Calcium Leucovorin, Sodium Folinate, Dacarbazine, Doxorubicin, Etoposide, Fluorouracil and Cisplatin. The Oncolo

Biocon. The Group's principal activity is to manufacture biotechnological products through fermentation based technology. The Group operates in three business segments: Enzymes, Active pharmaceutical ingredients and Contract research services. Active Pharmaceutical Ingredients accounted for 76% of fiscal 2006 gross revenues; Contract Research Services, 13% & Enzyme, 11%

Biocraft Laboratories is a domestic manufacturer of generic drugs. It manufactures various dosages of twenty three prescription drugs, and one prescription veterinary drug constituting an aggregrate of 68 products. The company's products are sold in various oral and topical dosage forms, including compressed tablets, two-piece hard-shell capsules, powders for oral solution or suspension, liquids and ointments. Its products can be divided into 11 categories: penicillin and semi-synthetic penicillin, cephalosporin, antibiotic, analgesic, anti-infective, anti-depressant, bronchial dilator, cardio

Biodelivery Sciences International, Inc.. The Group's principal activity is to develop and design drug delivery technology for pharmaceuticals, vaccines and over-the-counter drugs. The proposed drug delivery technology encapsulates or wraps the selected drug in a jellyroll-like structure termed as a cochleate cylinder. These drugs may be marketed under the brand name Bioral. The Group operates in the United States. Designs and develops drug delivery technology for pharmaceuticals, vaccines and over-the-counter drugs

Biodome specialises in the development of innovative products for various pharmaceutical and medicial uses especially the haemodialysis sector. The company has two subsidiaries 1) Biodome Distribution and 2) Biodome America. It became publicly held in June 1998. In 1998 it signed an agreement with various pharmaceutical companies launching a new series of products under the BIO-SET logo. Haemodialysis products accounted for 53% of 1999 revenues; various services, 27%; traditional products, 10% and BIO-SET products, 10%.

Life sciences and biotechnology resource for e-business services, career and employement services, e-commerce solutions.

Biogen IDEC Inc.. The Group's principal activity is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The Group's two commercial products, Rituxan (r) (rituximab) and Zevalin (r) (ibritumomab tiuxetan) are for use in the treatment of certain B-cell non-Hodgkin's lymphomas (B-cell NHLs). Rituxan is a genetically engineered, chimeric murine/human monoclonal antibody designed to harness the patient's own immune mechanisms to destroy normal and malignant B cells. Zevalin, the Group's radioimmunot

Biomatrix, Inc., develops, manufactures, markets and sells a series of proprietary viscoelastic products called "hylans". Hylans are the second generation of viscoelastics used in medicine and are characterized by significantly enhanced physical properties such as elasticity, viscosity and pseudoplasticity. These products are used in therapeutic medical applications and skin care. The wide range of patented products are in the form of fluids, gels and solids. The company's operations consist of therapeutic medical products, skin care intermediate products and toxicity testing. Of late, a signi

Biopharmica Ltd. The Company's Principal Activities Are The Commercialization of Biomedical Research And Development of Products to Detect And Treat Breast Cancer, Colorectal And Prostate Cancer Through Its Project With The University of Western Australia

Biora AB. The Group's principal activities are developing, manufacturing and selling biotechnology products to dentists and dental hygienists. The Group's principal product is Emdogain/Emdogain Gel which is based on a natural enamel matrix protein that is used to treat periodontal disease. The Group sells its products in the United States, Germany and Japan. Develops and manufactures and sells pharmaceutical products to dentists and dental hygienists

The glossary was developed to keep pace with the ever-evolving language of biotechnology. The glossary is the most up-to-date glossary related to biotechnology

Biovail Corporation. The Group's Principal Activities Are to Develop, Manufacture And Distribute Pharmaceutical Products. The Group Develops Generic Formulations of Medications For The Treatment of Chronic Medical Conditions. The Services of The Group Inc

Bioveris Corporation. The Group's principal activities are to develop, manufacture and market its M-SERIES(R) family of products. These products serve as a platform for diagnostic systems to be used for the detection and measurement of biological or chemical substances. It incorporates its technologies into its instrument systems, tests and reagents, which are the biological and chemical components used to perform such tests. The products are used in clinical diagnostics and non-clinical diagnostics markets. In the Clinical diagnostics markets the products are used for testing of patient sampl

Boehringer Ingelheim. The Group's principal activity is to manufacture, research and market of pharmaceutical products. The Group operates in two segments: Human Pharmaceuticals and Animal Health. Human Pharmaceuticals segment is sub divided into Prescription medicines, Consumer Health Care and Industrial Customer activities, which comprises chemicals, biopharmaceuticals and pharmaceutical manufacture. Animal Health segment introduces new products and product concepts for the treatment and prevention of diseases for animals. The Group also offers treatments for cancer and AIDS.

Boehringer Mannheim GmbH manufactures laboratory and therapeutic systems. This company has foreign subsidiaries in America, Far East, Africa and Europe. Laboratory systems accounted for 32% of 1992 revenues; therapeutic products, 32%; medical systems, 24%; biochemical products, 10% and other, 2%.

Boehringer Mannheim India Limited manufactures and markets pharmaceutical preparations in various forms and bulk pharmaceutical chemicals in collaboration with Boehringer Mannheim GmbH and Knoll AG of Germany. Pharmaceutical preparations accounted for 99% of fiscal 1995 gross revenues and bulk pharmaceutical chemicals, 1%.

Boryung Pharmaceutical Company Limited. The Company's principal activities are manufacturing and selling medicinal medicaments such as gelfos, cinalong, astrix and influenza H.A. vaccine. Other activities include food processing business and driving academy. Manufactures and distributes medicinal medicaments

Bradley Pharmaceuticals, Inc.. The Group's principal activities are to acquire, develop and market prescription and over-the-counter products in niche therapeutic markets. The Group serves the dermatology, podiatry, gastroenterology and women's health market through its subsidiaries. The Group operates in two segments: Doak Dermatologics and Kenwood Therapeutics. The Doak Dermatologics segment develops therapies for dermatology and podiatry. The Products of the Doak Dermatologics segment include ADOXA(R), KERALAC(R)/ KEROLTM, SOLARAZE(R), ZODERM(R), LIDAMANTLE(R), and ROSULA(R) .The Kenwood Th

Bristol-Myers Squibb Company. The Group's principal activities are to produce and distribute pharmaceuticals and other healthcare related products. The Group operates in three reportable segments: Pharmaceuticals, Nutritionals and Other Healthcare. Pharmaceuticals segment manufactures, distributes and sells branded pharmaceuticals. Nutritionals segment manufactures, markets, distributes and sells infant formulas and other nutritional products, including the entire line of ENFAMIL products. Other Healthcare segment consists of ConvaTec, Medical Imaging and Consumer Medicines. ConvaTec manufactu

Broad Intelligence International Pharmaceutical Holdings Ltd. The Groups principal activity is the manufacture, sale and research and development of pharmaceutical products under the brand name Nan Shaolin in China.

Bukwang Pharmaceutical Company Limited. The Company's principal activity is the manufacture of pharmaceutical, oral hygiene and cosmetic products. Chioxtasid acctd for 17% of fis 2006 revs;reganonhyutak,10%;paradontax8%;orfil,4%;anti-plaque3%;azeptine3%;nvelbine3%& other,52%

THE RESEARCH, DEVELOPMENT & COMMERCIALIZATION OF PHARMACEUTICAL FORMULATIONS UTILIZING ITS PROPRIETARY HIT & HILT TECHNOLOGY

Cangene Corporation. The Group's Principal Activities Are to Develop And Distribute Hyperimmune Products And Recombinant Biopharmaceuticals. Hyperimmune Products Are Specialty Antibody Preparations Made From Plasma Products. Recombinant Protein Products A

Cederroth International AB manufactures and markets health-food, hair-care, oral hygiene, skin-care, wound dressing and other related products. The company is a subsidiary of Alberto-Culver Company, the USA, and operates in Scandinavia, The Netherlands, Spain and Switzerland.

CONTRACT PRODUCTION SERVICES ACCOUNTED FOR 58% OF FIS 2000 REVENUES; CONSUMABLE SALES, 25%; SYSTEM SALES, 14% AND OTHER, 3%

Cellmetrix, Inc.. The Company develops and markets clinical testing applications and automated laboratory systems for detection, diagnosis and treatment of human diseases. In September 1999, the company acquired LungCheck Inc, which owns the LungCheck(R) technology. This technology is used for detecting Lung diseases such as cancer and provide a specialised sputum cytology laboratory service which includes assessment of pulmonary health of lung cells. Prior to the acquisition of LungCheck, the Company was software and technology consultancy firm specializing in providing ergonomic solutions to

Celltech Group PLC. The Group's principal activity is the ongoing research and development of novel therapeutic products for human use and the manufacture and sale of prescription pharmaceutical products. The Group operates in the United Kingdom, the United States of America and Rest of Europe. Its products are CDP870, CDP484, CDP323, PDE4, CDP146, CDP791, CMC-544, Xyrem, Codeprex, Equasym XL and CDP923. On 26-Feb-2003, the Group acquired Oxford GlycoSciences PLC. Researches and develops novel therapeutic products for human use and manufactures and sells prescription pharmaceutical products

Centocor, Inc. is a biopharmaceutical company which develops and commercializes novel therapeutic and diagnostic products and services. The company primarily focuses on monoclonal antibodies and DNA-based products for healthcare needs. Centocor develops products for infectious, cardiovascular disease and cancer. The company's products include ReoPro - used in the treatment of cardiovascular disease to prevent blood clots, Avakine - used in the treatment of rheumatoid arthritis and inflammatory bowel diseases such as Crohn's disease and Panorex - a monoclonal antibody that targets metastatic co

Chang An Information Industry (Group) Company Limited. The Group's principal activities are the research, production and sale of medicines and provision of medical outpatient services. Other activities include the manufacturing, developing and selling of aluminum oxide, electronic communication products and computer software, hardware and systems, provision of labor, restaurant, high technology or medical information and consultation services, real estate business, local and international trading and investing in medical equipment.

Changchun High New Technology Industries. The Group's Principal Activities Are The Manufacture And Distribution of Biological And Chinese Medicine. It is Also Engaged in The Technical Consultancy, Hotel And Restaurant, Tourism, Advertising, Training And I

Chengdu Hoist Group Co.. The Group's Principal Activities Are The Manufacture And Sale of Chinese And Western Medicines And Preparations, Chinese Medicinal Materials, Animal Medicines And Bioengineering Products. Other Activities Include The Development A

Chengzhi Co., Ltd.. The Group's Principal Activities Are The Development, Manufacture And Market of Life Science And Technology Medicines, Biological Pharmaceuticals, Chinese And Western Medicines And Biochemical, Health And Nutrition Products. Other Acti

Chine Medical and Bio Science Limited Formerly known as China Medical Science Limited. The Group's principal activities are the development, production, sale and distribution of human and veterinary drugs. Other activities include manufacture and distribution of packaging materials for infusion medicine. Operations are carried out in People's Republic of China. But during the year, the Group decided to dispose of all its human drugs and packaging materials businesses and thereafter to focus its operations on veterinary drugs and animal vaccines. Veterinary drugs accounted for 100% of fiscal 20

China National Medicines Corp., Ltd.. The Group's Principal Activities Are The Production And Distribution of Medicine, Chemical Medicine, Western Medicine Preparation, Bio-Chemical Medicine, Bio-Medicine And Chinese Patent Drug. It Also Imports And Expor

China Pharmaceutical Group Limited. The Group's principal activities are the manufacture and sale of pharmaceutical products. Other activity includes investment holding, provision of pharmaceutical research and development services and sewage treatment. Products include vitamin C, penicillin and cephalosporin. Its products are available in PRC, Europe, America and Asia. Bulk Drugs accounted for 65% of 2006 revenues; Finished Drugs, 35% and Others, nominal

ChiRex Inc. manufactures pharmaceutical ingredients and provides process research and development on contract basis. The operations of the company are broadly organized into two divisions: Manufacturing and Development. The manufacturing division produces bulk active pharmaceutical ingredients. The development division provides drug substance development research at any stage from discovery support and process R&D to manufacture of material for clinical trails. The company has operating facilities in Boston, Massachusetts, Malvern, Pennsylvania, Dudley, England and Scotland manufacturing more

Chiroscience Group plc is a pharmaceutical company primarily utilising its diverse technology platform to discover and develop novel medicines for improved healthcare. The group has three main activities: Chiroscience R&D based in Cambridge and Stevenage in England and in Seattle, Washington in the United States of America (discovers and develops innovation small molecule drugs and related diagnostics); Rapigene (creates and provides genomic technologies and services to partner companies and drug discovery programmes) and ChiroTech (provides chiral technology services to customers). Chiral tec

Chong Kun Dang Pharmaceutical Corporation. The Group's principal activity is manufacturing pharmaceutical products. Products include penicillins, antibiotics, antivirals, anti tuberculosis, cardiac drugs, therapeutics for osteoporosis, vitamins, tonics and minor tranquilizers. Manufactures pharmaceutical products

Chongqing Huapont Pharm. Co., Ltd. The Group's Principal Activities Are The Research, Production And Sale of Dermatology Department, The Tuberculosis Department And The Tumor Department's Chemical Medicine Products.

Chongqing Taiji Industry (group). The Group's Principal Activities Are The Processing And Selling of Chinese Prepared Medicines, Western Medicines And Health Care Products, Processing of Medical Packaging Goods And Selling of Medical Machines. Other Activ

Chrysalis International Corporation, is a contract research organisation providing a broad portfolio of integrated drug development services primarily to the pharmaceutical and biotechnology industries. The company generates substantially all its revenues from its drug development services and currently provides services for clients in 26 countries. The company provides preclinical services in toxicology, pharmacology and immunology and licenses its proprietary DNA Microinjection technology, used in pharmaceutical and biotechnology industries. The company acquired BioClin Inc., BioClin Europe

Circa Pharmaceuticals Inc develops, manufactures and markets solid dosage prescription generic drugs largely to drug wholesalers, private label distributors and government agencies.

Cistron Biotechnology, Inc. is a development stage, biotechnology company. The company manufactures and markets diagnostic and therapeutic products for cancer, arthritis and other autoimmune disease research. The company uses recombinant DNA and immunological techniques to explore certain cytokines that may have therapeutic or diagnostic applications. The principal research products consist of interleukin-1 beta ("IL-1"), a lymphokine which initiates the immune response, monoclonal and polyclonal antibodies, and an assay kit that measures IL-1 levels. Products of the company are sold to pharma

Controladora de Farmacias(COFAR). The Company's principal activities are carried out through the following divisions: Pharmaceutical involves the operation of pharmacies and drug stores and the purchase, sale, production and distribution of all types of medicinal, pharmaceutical and chemical products. Health, hygiene and personal care involves the distribution of health, hygiene, perfumes and personal care products. Pharmaceutical accounted for 86% of 2002 revenues and health, hygiene and personal care, 14%

Copley Pharmaceutical, Inc. develops, manufactures, markets and distributes multi-source pharmaceutical products. The company became publicly held on 21st October 1992. The products include prescription and over-the-counter drugs and are available in a variety of dosage forms consisting of capsules and tablets, solutions, syrups, elixirs, jellies, creams, ointments, lotions, powders and aerosols. The company's products include diabetes therapy drugs, antihistamines, skin and mucous membrane agents, anti-infective agents, cardiovascular drugs, central nervous system agents and prescription vita

Corgentech, Inc.. The Group's Principal Activity is The Discovery, Development And Commercialization of a New Class of Therapeutics Called Transcription Factor Decoys, or TF Decoys. TF Decoys Are Synthetically Manufactured Short Strands of Dna That Specif

Cotherix, Inc.. The Group's principal activities are licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Its product, Ventavis (iloprost) Inhalation Solution approved by the FDA is used for the treatment of pulmonary arterial hypertension (PAH), a disease characterized by severe constriction of the blood vessels of the lungs, in patients with New York Heart Association (NYHA) Class III or IV symptoms. Ventavis is an inhaled formulation of iloprost, a synthetic compound that causes blood vessels to dilate. Group began s

Crescendo Pharmaceutical Corporation develops and commercializes human pharmaceutical products through licensing to ALZA Corporation. The products of the company are combined with ALZA's drug delivery technologies with available therapeutic agents. The products of the company are OROS oxybutynin, DUROS leuprolide, OROS methylphenidate, E-TRANS LHRH, E-TRANS macroflux insulin, E-TRANS fentanyl. The company is a development stage company and became publicly held in 1997.

Cytokinetics, Inc.. The Company's principal activity is to develop small molecule therapeutics for the treatment of cardiovascular diseases and cancer. The Company's drug development pipeline consists of a drug candidate for the treatment of heart failure, being developed in both an intravenous and oral formulation and two drug candidates and a potential drug candidate for the treatment of cancer. The cytoskeleton is a complex that plays a fundamental role within every human cell. It's focuses on the cytoskeleton, which enables it to develop safer and more effective drugs for the treatment of

Cytomyx Holdings PLC. The Group's principal activity is providing outsourced research and development to the pharmaceutical industry and is a distributor for goods used in the life science industry. The Group provides a range of products and services that are used by its clients in the pharmaceutical industry to enhance their drug discovery productivity. These solutions enable clients to make better-informed decisions during drug development, through enhanced understanding of the role of gene and protein targets in disease progression and by being able to predict and eliminate drug candidates

DA AN Gene Co.,ltd. Of Sun Yat-Sen University. The Group's Principal Activity is The Research, Development And Production of Biomedicine. It is Also Involved in The Development And Application of Gene Diagnostic Technologies And Related Products Such as H

Dabur India Limited. The Group's principal activity is to manufacture health care, personal care and food products. The Group operates in three major segments: Fast Moving Consumer Goods, Food and Other. The Group's products include health supplements, digestives, baby care, Hare care, Skin care and Oral care products. The major brands of the Group include Dabur, Vatika, Hajmola, Anmol and Real. On 01-Apr-2005, the Group acquired Balsara Home Products Limited. Fast Moving Consumer Goods accounted for 87% of 2006 gross revenues; Foods, 9% and Other, 4%

DEVELOPS, MANUFACTURES AND MARKETS IN VITRO DIAGNOSTIC EQUIPMENT, REAGENTS, CONSUMABLE SUPPLIES AND SERVICES WORLDWIDE

Daewon Pharmaceutical Co., Ltd.(DWPH). The Company's principal activity is the manufacture and distribution of medicine and medical aid equipment as well as healthy aid food. It is also engaged in real estate leasing and import/export business.

Dainippon Sumitomo Pharma Company Limited Formerly known as Dainippon Pharmaceutical Company Limited. The Group's principal activities are to manufacture and marketing of pharmaceuticals, diagnostics, veterinary products, feeds and feed additives, food additives and chemicals. The operations are carried out through the following divisions: Pharmaceuticals includes pharmaceutical chemicals, general pharmaceutical products, diagnostic pharmaceuticals and other includes food additives, research and testing materials and feeds. Pharmaceuticals accounted for 78% of fiscal 2006 revenues and other, 2

Dalian Merro Pharmaceutical Co., Ltd.. The Group's principal activities are manufacturing and distributing pharmaceutical products like tablets, syrup, capsules, antibiotics, syringes, diagnostic medicine, epidemic preventive health products, blood supplements and others. Other activities include distribution of medical equipment and production and distribution of chemical-use glasses.

Davi Skin, Inc.. The Group's principal activity is to develop natural grape based skin care line. It is a development stage company. The Group is currently in the plan of developing skin creme product line. These products include Cleanser, Facial scrub, Eye cream, Revitalizing Moisturizer; Daily Moisturizer with sun protection, Intensive treatment serum and Purifying Clay Mask. Its products consist of all natural grape-based luxury skin care line. It operates as the wholly owned subsidiary of BMW Medical, Inca. Develops natural grape based skin care line

Dawnrays Pharmaceutical (Holdings) Ltd. The Group's principal activities are the development, manufacture and sale of non-patented chemical medicines including cephalosporin in bulk medicine and powder for injections forms. Operations are carried out in the People's Republic of China.

Dechra Pharmaceuticals PLC. The Group's principal activity is manufacturing and selling pharmaceuticals products. Pharmaceutical product brands include Equipalazone, Felimazole, Vetoryl, Vetcom Windows, Handyscan and Vet2Pet. The Group also markets and sells veterinary equipment and related services including computer systems, predominantly to the United Kingdom veterinary market, but also to overseas markets. The services operation stocks a range of over 12,000 products including pharmaceuticals, pet products, consumables and accessories. Services accounted for 93% of fiscal 2006 revenues and

Dexter Corporation. The principal activities of the Group are the development and manufacture of precise, reproducible biological and biochemical products used in applications of life sciences discovery, development and production process for research and commercial applications; proprietary formulation and manufacture of long-fiber, wet formed and hydroentangled products, primarily for use in the food packaging, medical and hygiene markets; and the formulation and processing of specialty adhesives, coatings and encapsulants primarily for use in the aerospace and electronics markets.

Dey, Inc.. Dey, Inc. develops, manufactures and markets prescription drug products for the treatment of respiratory diseases and related allergies. The company manufactures sterile, unit dose inhalation solution products, manufactured using aseptic form-fill-seal technology. Products of the company is marketed to large institutional purchasers, wholesalers, group purchasing organizations, chain pharmacies, health maintenance organizations and home health care organizations. During the year, the company transferred the assets and certain liabilities of its hypothyroid product business at book v

Diasense, Inc.. The Group's principal activity is to develop and market noninvasive glucose sensor for use by diabetics. The Group is in the developmental stage. Its operations consist of research and development, marketing and intended sale of biomedical products and devices. The sensor would use electromagnetic technology to measure the concentration of glucose in human tissue without requiring the user to take a blood sample. The Group has registered for trademark named Diasensor and owns a patent entitled, Non-Invasive Determination of Glucose Concentration in Body of Patients. The Group c

Diatide, Inc. discovers and develops and commercialises proprietary radiopharmaceutical products for the treatment of hazardous diseases like cancer and cardiovascular diseases. The company is using its technology in peptide engineering and radiolabelling chemistry for the development of novel nuclear medicines and trying to develop programs at large existing markets and aims at establishing clinical utility and advantages of techtides which is a product of the company. License fees accounted for 62% of 1998 revenues; sponsored research, 31%; research grants, 4% and drug sales, 3%.

Divi's Laboratories. The Company's principal activity is to manufacture and sell Active Pharma Ingredients and Intermediates. The products of the Company include CIS(+)Hydroxy Lactum, Naproxen and Dextromethorphan HBR. The Company's plants are located at Nalgonda district and Visakhapatnam district in Andhra Pradesh. Manufactures and sells Active Pharma Ingredients and Intermediates

Dong Sung Pharm Corporation. The Company's principal activities are manufacturing and distributing of medical medicaments, cosmetics and pharmaceutical products.

Donlar Biosyntrex Corporation Formerly known as Biomune Systems, Inc.. The Group's principal activity is to commercialize biodegradable polymers, known as thermal polyaspartates. The Group manufactures and markets these polymers to agricultural, industrial and consumer markets. The Group also is engaged in the distribution and sale of biologic nutraceutical supplements. The Group sells these products primarily to nutritional companies located in the United States of America. The Group has discontinued these nutraceutical operations during 2002. Commercializes biodegradable polymers

Dragon Pharmaceutical Inc. The Group's Principal Activities Are to Develop, Manufacture And Market Pharmaceutical Products in China And Developing Countries. Products of The Group Are Focused on Commercializing Human Proteins For Therapeutic Use. The Grou

Drogasil S.a.. The Company's Principal Activity is to Sell, Market And Distribute All Types of Pharmaceutical And Chemical Products, Perfumes And Fragrances.

Dura Pharmaceuticals, Inc. is a specialty respiratory pharmaceutical and pulmonary drug delivery company. The company develops and markets prescription pharmaceutical products for the treatment of allergies, asthma, hay fever, chronic obstructive pulmonary disease, the common cold and related respiratory ailments. The company currently sells 10 prescription product lines and has a separate mail service pharmacy, Health Script Pharmacy Services, Inc., which dispenses respiratory pharmaceuticals. During 2000 the company acquired Spiros Development Corpration II, Inc. Pharmaceutical products acco

DXN Holdings Bhd. The Group's principal activities are the cultivation of Ganoderma and Mycelium and manufacturing, selling and trading of health supplement and other products and the market of these products on a direct sales basis. Other activities include housing developer, building contractor, wholesaler and retailer of stationary, household items, hardware toiletries, gift and accessories, travel agent and tour operator, information technology adviser and consultant and investment holding. The Group operates in Malaysia, India, Philippines and other countries.

Dynavax Technologies Corporation. The Company's principal activity is to discover, develop and commercialize TLR-9 agonist-based products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases. The clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. The products in pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, currently in major large-scale clinical trial in ragweed allergic adults and in a s

E-Z-EM, Inc.. The Group's principal activities are to develop, manufacture and market medical diagnostic products and therapeutic products. The diagnostic products are designed to facilitate the detection of physical abnormalities and gastrointestinal diseases. E-Z-EM segment supplies medical products used by radiologists, gastroenterologists and speech language pathologists for diagnostic imaging of diseases and disorders of the gastrointestinal tract. The diagnosis also includes testing for colorectal cancers and swallowing disorders. It operates in the United States, Canada, the United King

Eiffel Technologies Ltd. The Group's Principal Activities Are Conducting Research And Development Into re-Engineering of Currently Approved Drugs in The Pharmaceutical Industry Using Supercritical Fluid Technologies. The Group Operates in One Geographical

Eirx Therapeutics PLC. The Group's principal activity is discovering and validating genes that are involved in apoptosis and therefore potential targets for novel therapeutics. The Group creates intellectual property that it out licensees or seeks to exploit by other means including in-house drug discovery. The Group also provides contract research for third party pharmaceutical and therapeutics companies. The Group is also pursing preclinical studies with a number of anticancer compounds. These compounds, which act in the nanomolar range, act through a defined mechanism of action. The Group a

Pharmaceutical manufacturer of Elan Pharmaceuticals and Neurex Pharmaceuticals.

Eli Lilly and Company. The Group's principal activities are to discover, develop, manufacture and market pharmaceutical-based health care solutions. The pharmaceutical products include: Neuroscience, Endocrine, Anti-infective, Cardiovascular agents, Oncology and Animal Health. The Group specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices. The Group's pharmaceutical products are distributed through wholesalers. The Group's patents include Zyprexa, Prozac, Permax, Darvon, Humulin, Evis

Egenix, Inc. Formerly known as Epigen, Inc.. The Company's principal activities are developing products to monitor, diagnose and treat cancer in a more effective, less expensive and less invasive manner than other products. The Company has completed the basic development of an in-vitro diagnostic blood test for cancer that uses the Company's technology. The test will be used to monitor breast cancer and as a confirmatory test for prostate and breast cancer. The Company has also developed a series of monoclonal antibodies for use as a therapeutic vaccine to treat a broad range of human carcinom

Epigenomics AG. The Group's principal activity is to conduct molecular diagnosis for the early detection and treatment of cancer and other complex diseases. The Group's products are based on DNA methylation, which are aimed at making early detection and treatment easier, more accurate and more convenient for the patient. The Group compares patient's cells against healthy and sick reference samples, which enables an exact diagnosis of disease at a very early stage and provides physicians with essential information to help guide the appropriate therapy. In the year 2005, one of the Group's subsi

Epitope, Inc., through its biotechnology develops diagnostic tests and devices for the detection of Human immunodeficiency virus (HIV). The company's products include OraSure, an oral specimen collection device and EPIblot, a serum-based Western blot confirmatory test kit. The company's customers includes life insurance companies, prison systems, the military, and colleges and universities. The company markets its products in the United States, Canada, Europe, Asia, Latin America and other countries. International sales accounted for 2.5% and there was nominal exports during fiscal 1999. Oral

Essex Bio-Technology Limited. The Group's principal activities are the manufacturing and selling of biopharmaceutical products, organic and chemical formulated agricultural fertilizers.Other activity includes investment holding. Its operations are carried out in the People's Republic of China and the British Virgin Islands. Manufactures and sells biopharmaceutical products, organic and chemical formulated agricultural fertilizer

Euro Med Laboratories Philippines Incorporated. The Group's principal activity is manufacturing pharmaceutical products such as large and small volume parenterals and other solutions. Large volume parenterals are more commonly known as intravenous fluids. The Group also manufactures sterile water for injection and other solutions such as ophthalmic, inhalation, irrigation and dialysis. Other products include venipuncture sets, IV Administration sets and IV equipment, and bottled water. The Group also offers contract packaging services to both local and multinational companies for food, cosmeti

Evergood Products Corporation. The Group's principal activities are to manufacture, franchise, market and distribute branded and non-branded vitamins, minerals and dietary supplements. The Group operates in three segments: manufacturing, franchising and brand development. The Group manufactures substantially all of the vitamins and dietary supplements through its wholly owned subsidiary, Phoenix Laboratories, Inc. The Group markets and sells more than 1,200 products under its Great Earth (R) brand and more than 40 products under its Bodyonics (R) brand. The Group's products are sold through GN

Everpride Biopharmaceutical Company Limited. The Group's principal activities are manufacturing and trading of medicines. Other activity is investment holding. Manufacture and sell medicines

Evolve Oncology Inc Formerly known as Oncthera, Inc.. The Group's principal activity is to conduct research and development of pharmaceutical products to fight cancer. On 01-Mar-2003, the Group acquired EU Laboratories Limited and adopted its business plan, whereby the Group sold off and transferred all of its interests in the print industry it to its own shareholders. The Group is currently operating through two wholly owned subsidiaries: EU Laboratories Limited and Antibody Technologies Inc. The Group has four products in its portfolio: Evo 011 - monoclonal antibody; Evo 022 breast cancer co

Eyetech Pharmaceuticals, Inc.. The Group's principal activities are to develop and commercialize novel therapeutics to treat diseases of the eye. It is a biopharmaceutical company that specializes in ophthalmology and vision research. The Group is developing an advanced product, MacugenTM (pegaptanib sodium), for the treatment of the wet form of age-related macular degeneration (ADM) and diabetic macular edema (DME). Both AMD and DME are serious diseases of the retina that can lead to severe vision loss and blindness. The EyetechTM, Eyetech PharmaceuticalsTM and MacugenTM are the trademarks of

F.H. Faulding and Company Limited has manufactured and distributed health and personal care products since 1845. The products manufactured include injectible and orally taken pharmaceuticals including modified release products and other health and personal care products. It is Australia's only national pharmaceutical distributor supplying over 15,000 product lines. The company conducts its operations in Australia and in the United States of America and also commenced operations in the People's Republic of China. The company also provides retail management services and logistics management serv

Far East Pharmaceutical Technology Company Limited. The Group's principal activities are manufacturing and distribution of pharmaceutical products. Products include anti-viral drugs, anti-hypotensive drugs, Chinese patent medicines, antibiotics, analgesics and Chinese tonic liquor. Other activity includes investment holding. Operations are carried out in Hong Kong, the British Virgin Islands and the People's Republic of China. Majority of the Group's customers are based in the People's Republic of China. Manufactures and distributes pharmaceutical products

Farmitalia Carlo Erba SRL. Farmitalia Carlo Erba SRL is principally engaged in the manufacture and distribution of pharmaceuticals, both refined and uncompounded for the medical and veterinary sectors. Pharmaceuticals accounted for 87% of 1992 revenues; over-the-counter drugs, 5%; reagents, 5%; uncompounded drugs, 2% & veterinary and other drugs, 1%.

FDC Ltd. The Group's principal activity is the manufacture and sale of pharmaceutical products. These products include ophthalmic formulations like Pyrimon, Vanmycetin, Astham, others drugs and infant food formula for children suffering from lactose intolerance. It exports to over 50 countries, including the US, South Africa, U.K., Europe, Japan and more. Manufactures and sells pharmaceutical products

Fisons Plc manufactures and supplies ethical and proprietary medicines, veterinary products, analytical instruments, laboratory and educational scientific equipment, clinical diagnostic supplies, garden and horticultural products. Its products are marketed throughout the world. Laboratory supplies accounted for 40% of 1994 revenues; pharmaceutical products, 37%; scientific instruments, 21% and horticulture, 2%.

PROVIDES CONSULTING SERVICES TO PHARMACEUTICALS & DEVELOPS NOVEL APPLICATION DRUG DELIVERY SYSTEMS

Fuisz Technologies Ltd. develops, manufactures and commercializes pharmaceutical and consumer healthcare products and technologies. Through its unique drug delivery systems that include CERFORM and Shearform, the company conducts research and development on behalf of pharmaceutical and consumer healthcare companies. The company is focusing on Over The Counter products and is accelerating the development of Over The Counter products through its microsphere technology. In 1998, the company signed fifteen new agreements with major pharmaceutical partners besides launching four products through ne

Fuji Pharma Company Limited Formerly known as Fuji Pharmaceutical Company Limited. The Company's principal activity is to manufacture and sell prescription drugs including hormone agents, diagnostic drugs, bought-in products such as hormone agents, external diagnostic agents, external application drugs, antibiotics and chemotherapeutic agents, urogenital drugs, external skin drugs, circulatory drugs and other products.

Genaera Corporation. The Group's Principal Activity is to Develop Medicines For Serious Diseases From Genomics And Natural Products. The Research And Development Efforts of The Group Are Focused on Anti-Angiogenesis, Respiratory Diseases, Obesity, And Inf

DEVELOPS AND DISTRIBUTES NUTRITIONAL AND HEALTH RELATED PRODUCTS FOR HUMANS AND PETS

Genelink, Inc.. The Group's principal activity is to provide public the safe collection and preservation of a family's DNA material for later use by the family to identify and potentially prevent inherited diseases. It is a bioscience company, operates in the human molecular genetics market. The Group has developed a DNA Collection Kit for the collection of DNA specimens of its clients. The DNA Collection Kit(R) consists of several swabs, collection accessories, complete instructions and a mailing envelope; the kit and kit elements are bar coded to facilitate tracking, control and confidential

Genemedicine, Inc., develops a new class of pharmaceutical products which incorporate genes. The company develops non-viral gene therapies that provide clinical benefits in the treatment of human diseases such as cancer, neuromuscular disorders, pulmonary diseases and viral infections. The company's genemedicines are designed to be well-characterized pharmaceutical products that are directly administered to patients to cause the production and distribution of therapeutic proteins within the body. The company has strategic alliances with Corange International Ltd. and Syntex Inc. to develop and

Genentech Inc. The Group's principal activities are to discover, develop, manufacture and commercialize biotherapeutics for unmet medical needs. The Group manufactures and markets biotechnology products and licenses several additional products to other companies. Activase, AvastinTM, Cathflo Activase, Herceptin, LucentisTM, Nutropin Depot, Nutropin AQ, Nutropin, Protropin, Pulmozyme, RaptivaTM,TNKaseTM, Rituxan, etc. are some of the registered trademarks owned by the Group. The Group also provides certain customer service programs relating to products. The Group has foreign operations in Asia

Genepharm Australasia Ltd. The Company's Principal Activity is The Distribution of Generic Prescription Pharmaceuticals.

Genmab A/S. The Group's principal activity is to create and develop human antibodies for the treatment of life-threatening and debilitating diseases. The Group has numerous HuMax products under development to treat various cancers, infectious diseases, and auto immune and inflammatory conditions. It has established multiple partnerships to gain access to disease targets and develop novel human antibodies, including agreements with Roche and Amgen. An alliance with Medarex provides the Group with access to the UltiMAb Human Antibody Development System, an array of proprietary technologies for t

Develops innovative gene therapy products for the treatment of Hemophilia, Cancer, HIV/AIDS & other genetic disorders

Genzyme Corporation. The Group's principal activities are to develop, manufacture and market biotechnology products. It operates through five segments. Therapeutic products consist of products for genetic diseases and other chronic debilitating diseases. Renal consist of products that treat patients suffering from renal diseases, including chronic renal failure. Diagnostic/Genetics consist of vitro diagnostic products with an emphasis on point of care products for the in-hospital and out of hospital rapid test segment, clinical chemistry reagents and raw materials focused on the clinical labor

Genzyme-Molecular Oncology. The Group's principal activity is to develop cancer products with a focus on cancer vaccines, angiogenesis inhibitors and cancer pathway. These therapies are shaped through the integration of its gene discovery, gene therapy, small molecule drug discovery and protein therapeutic capabilities. The products are used to treat multiple types of cancer, minimize toxicity, side effects, complement both existing and novel therapies. The Group supplements its internal resources through collaborations with some of the world's preeminent scientists and clinicians in the field

Genzyme Tissue Repair Division develops and sells biological products used in the treatment of orthopedic injuries, such as cartilage damage and severe burns. The company is a operating division of Genzyme Corporation. Brand names under GTR's control include Carticel (used in cartilage repair), Articel wound dressings, Epicel skin grafts and Vianain debriding product (used in the treatment of burns).

Geopharma, Inc.. The Group's principal activities are to manufacture, pack and distribute private label dietary supplements, over-the-counter drugs and health and beauty care products. The Group develops and manufactures branded dietary supplements and health and beauty care products for distribution through various outlets. The Group's products are sold under the trademarks Lean ProteinTM, NutrisureTM, Physician PharmaceuticalTM 12-and Arth-AidTM. DexL-10, OxyFirm, formerly known as Oxylene, are the Group's dietary supplement lines and Lean Protein Bites, CarbSlim Crunch Bites and CarbSlim Co

Ginwa Enterprise Group Inc.. The Group's Principal Activities Are Manufacturing And Distributing of Bio-Pharmaceutics, Chinese And Western Medicine in The Form of Liquids to be Taken Orally, Capsule And Tablet, Health Products And Medicine Logistics. It i

Girindus AG. The Group's principal activities are to conduct research and development and to manufacture and sell pharmaceutical products and chemical intermediate products. The Group operates laboratories and pilot plant facilities for medchem, preclinical, clinical and radiosynthesis needs in Cincinnati, Ohio, USA. The Group has operations in Germany,Europe, USA and Others. Conducts research and development and manufactures and sells pharmaceutical and chemical intermediate products.

GlaxoSmithKline plc. The Group's principal activity is creating, discovering, developing, manufacturing and marketing pharmaceutical products and consumer health-related products. The Group's principal pharmaceutical products include medicines in the therapeutic areas of respiratory, central nervous system, anti-virals, anti-bacterials, anti-bacterials/anti-malarials, metabolic, vaccines, oncology and emesis, and cardiovascular and urogenital. Product brands includes Serevent, Wellbutrin, Lamictal, Requip, Combivir, Ziagen, Trizivir, Zeffix, Valtrex, Augmentin, Zinnat, Malarone, Lapdap, Avandi

Glycorex Transplantation AB. The Group's principal activities are the development, manufacture and marketing of drugs used in the field of organ transplantation. The Group's main products are GlycoSorb-ABO and GlycoSorb-Xeno. GlycoSorb-ABO is used to facilitate organ transplantation between different blood types; GlycoSorb-Xeno is used to facilitate organ transplantation from animals to humans.

Provides financial and business development services to its clients through its web site GopublicNow.com

Green Cross Corporation was founded in 1950 as Japan's first commercial blood banks and became a diversified international pharmaceutical company producing ethical drugs for delivery or administration by doctors and healthcare workers. The company merged into Yoshitomi Pharmaceutical Co., Ltd. on April 1, 1998. Its products were extensively used in the treatments of a wide range of ailments. As well as supplying whole blood for transfusions, Green Cross was also active in developing blood derivative products such as coagulation factors, immunoglobulin and albumin. In the mid 1960's, it expande

Green Cross Sang-A Corporation. The Company's principal activity is manufacturing of pharmaceutical products. Products include Gigafulvin Cream, Cool Type Man Gang Go Cataplasma, Doneo Soft Capsule and Diogel Suspension. Manufactures pharmaceutical products

Greenwich Pharmaceuticals Incorporated is a development stage pharmaceutical company whose primarily objective had been to identify, develop and market synthetic carbohydrate drugs that can be used to treat chronic autoimmune diseases. Following certain unfavourable events during the first half of 1994 related to the development and approval of compounds under development by the company, in June 1994, the company's business objective became the conservation of its resources in order to consummate a merger or other transactions which would maximize the value of the company's remaining assets. T

Gtx, Inc.. The Group's principal activity is the discovery, development and commercialization of therapeutics related to the treatment of serious conditions men's health conditions. The Group has two product candidates that are in human clinical trials, ACAPODENE(R) (toremifene citrate) and ANDARINE. The Group also developing another SARM product candidate, prostarine, for the potential treatment of benign prostatic hyperplasia. The Group is conducting preclinical studies required to support clinical trials Discovers, develops and commercializes therapeutic products

Guangxi Beisheng Pharmaceutical Co.. The Group's Principal Activities Are The Production And Distribution of Chinese And Western Medicine, Biological Pharmaceutical And Blood Products. It Also Produces And Sells Chemical Medicine, Body Tissue Building Mat

Guangzhou Baiyunshan Pharmaceutical Stock. The Group's Principal Activities Are The Research, Development, Manufacture And Sale of Chinese And Western Medicines, Chemical Raw Medicines, External Medicines, Children's Medicines And Health Care Medicines. O

Guilin Jiqi Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Chemical Raw Materials And Chinese Medicines And Preparations. Other Activities Include The Processing of Imported Packaging Materials; Manufacture And

Gull Laboratories, Inc., develops, manufactures and markets medical diagnostic test kits designed to detect infections caused by certain microbial agents such as viruses, bacteria or protozoa and to detect certain autoimmune disorders. The company's products are used by private laboratories and hospital clinical laboratories worldwide. Other operations of the company include manufacturing, distributing and selling reagents and related products to the industrial and scientific community. The company is a 62% owned subsidiary of Fresenius AG, a German company. In 1997, the company acquired certa

Hainan Haide Industry Company Limited Formerly Known as Hainan Haide Textile Industrial Company Limited. The Group's Principal Activities Are The Manufacture And Sale of Medicine And Medical Apparatus. Other Activities Include The Management of Hotel And

Hainan Haiyao Company Limited Formerly Known as Hainan Qingqi Haiyao Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Medicines Namely Precision Chemical Products, Herbal Medicines, Chinese And Western Medicines, Health Suppleme

MANUFACTURES, SELLS, MARKETS AND DISTRIBUTES GENERIC DRUGS THROUGHOUT THE UNITEDSTATES

Hanall Pharmaceutical Co., Ltd.(HAP). The Company's principal activities are the manufacture of medicinal medicaments such as cephazedone, proamin, BTXI, PN Twin No 3, and PN Twin No 1.

Handok Pharmaceuticals Co., Ltd.. The Company's principal activity is manufacturing of medicinal medicaments. Major products include Festal Forte, Reagent Apparatus and Munobal. Pharmaceuticals accounted for 48% of 2005 revenues; Reagent Apparatus, 8% and others, 44%

Hangzhou Huadong Medicine Co., Ltd.. The Group's Principal Activities Are The Manufacture of Chinese And Western Raw Material Medicines And Preparations And Sale of Chinese Medicinal Materials, Chinese Medicine Tablets And Patent Medicines, Chemical Raw M

Hanil Pharmaceutical Industry Company Limited. The Company's principal activity is the manufacture of pharmaceuticals and medicinal chemicals like drugs such as Cefotiam HCI, Diltiazem HCI, Pravastatin sodium and others. Other accounted for 54% of 2005 revenues; mevalotin, 20%; herben, 20%; and ceradolan, 6%

Hanmi Pharmaceutical Company Limited(HANMI). The Group's principal activities are manufacturing medicinal medicaments. Products include drinks, injections, soft and hard capsules, syrup and other. Manufactures medicinal medicaments

Health-Chem Corporation. Health-Chem Corporation operates through Transderm Laboratories Corporation which manufactures and develops controlled release products for the pharmaceutical industry. The company manufactures transdermal drug delivery systems and over the counter pharmaceuticals and cosmetic products. During the year 1998, the company discontinued the operations of its wholly owned subsidiary Pacific Combining Corporation. Export sales accounted for 5% in 1998. Transdermal nitroglycerin products accounted for 65% of 1998 revenues and over the counter pharmaceutical andcosmetic produc

Hemagen Diagnostics, Inc.. The Group's principal activities are to develop, manufacture, and markets medical diagnostic test kits. The Group has three different product lines. The Virgo product line consists of diagnostic test kits that are used to aid in the diagnosis of certain autoimmune and infectious diseases, using ELISA, Immunoflourescence and hemagglutination technology. The Raichem product line consists of a complete line of clinical chemistry reagents that are sold under brand name Raichem as well as under various OEM arrangements. The Analyst product line is an FDA cleared clinical

Henan Joyline & Joysun Pharmaceutical. The Group's Principal Activities Are The Research, Development, Production, Infusion And Distribution of Chinese And Western Medicines. Other Activities Include The Production And Sale of Chemicals For Plants And Pro

Henan Topfond Pharmaceutical, Ltd.. The Group's principal activities are processing, manufacturing and distributing of bio-fermentation pharmaceuticals, raw chemical pharmaceutical and preparation. Products of the Group include Western and Chinese herb finish products, synthetic chemical pharmaceuticals like Fleroxacin Tablet, Acetylspiramycin, Venoruton, Chlortetracycline, Spiramycin, Erythromycin, Thiocyanate, Diclofenac Sodium, Ciprofloxacin Lactate Injection and the like. These products are exported to Western Europe, Southeast Asia, South Asia, Hong Kong, Middle East, North Africa and Sou

A NATIONAL PHARMACEUTICAL MANUFACTURER FOR HOSPITAL & NURSING HOME PRODUCTS. SALES BREAKDOWN UNAVAILABLE

Holliday Chemical Holdings plc manufactures speciality organic and inorganic chemicals, dyes, intermediates, sulphur dyes, printing inks, dispersions, pharmaceutical and veterinary actives and fine chemicals. Activities of the Group are carried out in the United Kingdom, Germany, France, Spain and Russia. Organic compounds accounted for 51% of fiscal 1996 revenues and inorganic compounds 49%.

Hospira, Incorporated. The Group's principal activities are to develop, manufacture and market medication delivery systems, critical care devices and specialty injectable pharmaceuticals. The medication delivery systems consists of electronic drug delivery pumps, administration sets and accessories and infusion therapy products to deliver intravenous fluids and medications to patients. The critical care devices are used to monitor cardiac functions in critically ill patients. The specialty injectable pharmaceuticals include generic injectable pharmaceutical products and proprietary injectable

Hubei Guangji Pharmaceutical Co., Ltd.. The Company's Principal Activities Are The Manufacture And Sale of Pharmaceutical Raw Materials, Veterinary Raw Material Medicines, Pharmaceutical Preparations, Food, Feeds, Additives And Fine Chemicals. Other Activ

Hubei Qianjiang Pharmaceutical, Ltd.. The Company's Principal Activities Are The Manufacture And Sale of Eye Drops, Injections, Tablets, Capsules, Frozen Dry Powder For Injection, Raw Material Medicines, Granules, Plastic Packaging Goods And Health Bevera

Hunan Dongting Aquaculture Co., Ltd.. The Group's Principal Activities Are Breeding, Processing And Selling Freshwater Fish, Aquatic Products And Waterfowl. Major Aquatic Products Include Crabs, Bighead Carp, Grass Carp, Silver Carp And Carp. It is Also E

Hunan Guoguang Ceramic Group. The Group's Principal Activities Are The Manufacture And Sale of Daily-Use Porcelain, Electric Ceramics, Art Ceramics, Construction Ceramics, Sanitary Ceramics, Fire-Resistant Materials, Paper Boxes, Ceramic Transfer Papers A

HYMEDIX, Inc.. The Group's principal activities are to develop and commercialize biomedical and skin care products based on proprietary advanced hydrogels. The hydrophilic polymers are biocompatible and highly versatile and enable the Group to develop and manufacture products and components with advantageous characteristics for medical and other markets. The Group has two product lines: Wound Care products and Skin Care products. License, royalty and distribution fees accounted for 50% of 2001 revenues; hydrogel and skin care, 45% and research and development, 5%. License, royalty & distributi

Hyundai Pharmaceutical Company Limited Formerly known as Hyundai Pharmaceutical Industrial Company Limited. The Company's principal activity is manufacturing of medicinal medicaments. The Company's main medical products include Tenormin tablets, for hypertension and angina pectoris; Zestril tablets for hypertension and congest heart failure; Elroton tablets, for coronary artery diseases; Surfolase capsules, for acute or chronic respiratory diseases resulting from respiratory obstruction and disturbance in mucous secretion; and Norlevo tablets, for oral emergency contraceptives, among others. T

Idenix Pharmaceuticals, Inc.. The Group's principal activities are to discover, develop and commercialize drugs for the treatment of human viral and other infectious diseases. Its current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus. Discovers, develops and commercializes drugs for the treatment of human viral and other infectious diseases

IDL Biotech AB. The Company's principal activities are the development, manufacture and marketing of products for testing and treatment of mainly cancer and typhoid fever. The trade marks include TPS Elisa, TPS Irma, TPS EIA, TPS Immulite, UBC Rapid and TUBEX.

Il Dong Pharmaceutical Company Limited. The Group's principal activity is manufacturing of medicinal medicaments. Major products include Flumarine, Aronamin Gold and Curan. Aronamin Gold accounted for 12% of fis 2006 revenues; Flumarine, 12%; Curan 8% and Others, 68%

IL-Yang Pharmaceutical Company Limited. The Company's principal activities are developing and manufacturing pharmaceutical products such as Azintal Tab, Wonbi-F and Youngbichun. Other activities include manufacturing health food and cosmetics. Develops and manufactures pharmaceutical products; also manufactures health food and cosmetics

Ilsung Pharmaceuticals Company Limited(ISP). The Company's principal activity is the manufacture of medicinal medicaments. Products include Augementin, II sung lopamiro and onealfa-100c.

Imcor Pharmaceutical Company Formerly Known as Photogen Technologies Incorporated. The Group's Principal Activity is Focused on Developing And Marketing Medical Imaging Pharmaceutical Products. The Products Include Imagent (r), Approved by The Food And Dr

Immunex Corporation develops, manufactures and markets innovative human therapeutic products for the treatment of cancer, infections and autoimmune diseases. Leukine is the company's principal commercial product which was approved by the FDA in 1991 and is used to treat bone marrow transplant. The company is testing four new proprietary biotechnology products in human clinical trials; PIXY321, a patened colony stimulating factor fusion protein, soluble IL-1 receptor (IL-1R), soluble IL-4 (IL-4R) and a soluble tumor necrosis factor receptor fusion protein (TNFR).

Impax Laboratories, Inc.. The Group's principal activity is to develop, manufacture and market specialty prescription pharmaceutical products utilizing its own formulation expertise and unique drug delivery technologies. It is a technology-based, specialty pharmaceutical Group focused on the development and commercialization of generic and brand name pharmaceuticals, utilizing the controlled-release and other in-house development and formulation expertise. It focuses on selected controlled-release generic versions of brand name pharmaceuticals. The Group develops products for the treatment of

DISCOVERS AND DEVELOPS THERAPEUTICS FOR THE TREATMENT OF BOWEL DISEASES, LIVER DISORDERS, STROKE, ASTHMA AND REPERFUSIONINJURY

Inex Pharmaceuticals Corp. The Group's Principal Activity is to Commercialize Proprietary Drugs And Drugs Delivery System to Improve The Treatment of Cancer. The Group's Product Candidates Utilize Both Already Approved, Conventional Pharmaceuticals in Com

Inflazyme Pharmaceuticals Ltd.. The Group's Principal Activities Are to Discover, Develop And Commercialize Pharmaceutical Products to Treat Serious Auto-Immune And Inflammatory Diseases. These Pharmaceutical Products Are Used to Cure Asthma, Allergic Rhi

Inner Mongolia Yili Science & Technology Industry Co., Ltd.. The Group's principal activities are the developing, processing and selling of pharmaceutical products and food and health supplements. Other activities include the manufacture and sale of chemical industry products; provision of engineering construction services; developing and processing of ecological organisms; planting, purchasing and sub-contracting of licorice roots and other Chinese herbal medicine and export of manufactured products and related technologies, machinery equipment, meter apparatus and spare parts. Operations of

Manufactures dietary supplements, over-the-countery drugs & health & beauty care products

Institut Merieux SA develops and distributes vaccines, serums & therapeutic products for use as human and veterinary medicine. The company is also involved in poultry genetics and operates in over 150 countries. In addition, it is engaged in several research and development programmes, especially in the area of human medicine. Human healthcare products accounted for 62% of 1993 revenues; animal healthcare products, 26%; poultry genetics, 11% and other, 1%.

Instituto Sanitas Sa. The Group's Principal Activities Are The Preparation And Sale of Serum, Vaccines, Biological Products, Chemicals And Other Pharmaceutical And Laboratory Products, Preparation of Alimentary Products For Breast-Fed Babies And Manufactu

MANUFACTURES, MARKETS & SELLS VITAMINS, NUTRITIONAL SUPPLEMENTS & HERBAL PRODUCTS

IPCA Laboratories Limited. The Group's principal activities are to manufacture and distribute drugs and pharmaceuticals. The products include tablets, capsules, basic drugs, orals, liquids and injectables. The operational facilities of the Group are located in Ratlam and Indore at Madhya Pradesh, Gandidham at Gujarat and Dadra and Nagar Haveli. Manufactures and distributes drugs and pharmaceuticals

PETROLEUM PRODUCTS ACCOUNTED FOR 83% OF 89 REVENUES & MACHINERY & EQUIPMENT, 17%

Isotope Solutions Group, Inc. Formerly known as EDG Ccpital, Inc... The principal activity of the group is to develop anti-cancer nuclear pharmaceutical technologies. Nuclear pharmaceuticals are drugs that are made radioactive by attaching an isotope to the drug. The Group currently owns patent rights for two drugs Cisplatin and Colloidal. Cisplatin is a platinum-based drug used in the treatment of cancers that integrates into the DNA of tumor cells and kills the cells. Colloidal is an isotope of phosphorus into a colloid. Colloidal is applied to cancer through a process called infusional brac

ISTA Pharmaceuticals, Inc.. The Group's principal activities are to discover, develop and commercialize new remedies for diseases and conditions of the eye. The Group develops ophthalmic drugs based on a group of natural enzymes called hyaluronidase that is used to treat diseases and conditions such as vitreous hemorrhage, diabetic retinopathy, corneal and keratoconus. The major products of the Group are Istalol, Vitrase, Xibrom, Ecabet sodium, Caprogel and Strong Steroid. Istalol is used for the treatment of glaucoma. Vitrase is a formulation of hyaluronidase used for the treatment of vitreou

Istituto Farmacologico Serono (Serono) SpA produces pharmaceuticals for the medical, veterinary and diagnostic fields and engages in research operations. In 1994 the company reduced its diagnostics section, disposing of the subsidiary, Ares Serono Diagnostici SpA. The consolidated group is composed of eight companies in all, only one of which - Istituto Farmacologico Serono Netherland B.V. (Amsterdam, Netherlands) is located outside Italy. The company manufactures both finished products for the export market and raw materials for its subsidiaries in Italy and abroad. Pharmaceutical sector acco

Ivax Corporation. The Group's principal activities are the research, development, manufacture and marketing of pharmaceutical products. It manufactures and markets several brand name pharmaceutical products and a wide variety of brand equivalent and over-the-counter pharmaceutical products, primarily in the United States, Europe and Latin America. The Group has manufacturing operations in Argentina, Chile, China, the Czech Republic, Germany, Ireland, Italy, Mexico, the United Kingdom, the United States, Puerto Rico and the U.S. Virgin Islands and Venezuela. The products are sold primarily to w

Je Il Pharm. Co., Ltd.. The Company's principal activities are the manufacture and sale of medicinal chemicals and antibiotics. Its products include Cefen, Je II Pap and Yamatetan.

Jiangsu Hengrui Medicine Co., Ltd.. The Group's principal activities are developing, manufacturing and distributing raw chemical pharmaceuticals, injections, tablets, capsules, western medicines, medicine packaged materials and raw medicines. Other activities include manufacturing and selling SP aluminum foil, PTP aluminum foil, OP protection preparation and VC adhesive. Injected Medicine acctd for 78% of 2006 gross revs; Tablet, 19%, Raw Medicine, 3% & Other, nom

Jiangsu Kanion Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Chinese Pharmaceutical Products. Other Activities Include The Export of Chinese Medicine And Health Products And Import of Materials And Machinery Eq

Jiangsu Liahuan Pharmaceutical Co., Ltd.. The Group's principal activities are researching, developing, producing and distributing of medicines in the form of capsules, tablets, pills, pellets and suppository. Other activities include manufacturing of auxiliary raw medicines, providing technical scientific consultation, manufacturing and selling of equipment for pharmaceutical and chemical industries.

Jiangxi Jiangzhong Pharmaceutical. The Group's Principal Activities Are The Manufacture And Sale of Pharmaceutical Products. Main Products Consist of Chinese, Water-Soluble And Botanical Medicines; Penicillin Raw Materials And Injection; Capsules; Antibio

Jilin Aodong Medicine Industry (Group) Co., Ltd.. The Group's principal activities are developing, manufacturing and selling of medicines. It also manages the collection of toll fee on road, highway and bridges and constructs public road. Other activities include the export of commercial goods such as tranquilizer, capsules and ginseng; development of real estate; maintenance and repair services of machinery; sale of wine and provision of food and beverage and transport services. Operations are carried out in the People's Republic of China and other countries.

Jilin Pharmaceutical Company Limited Formerly Known as Jilin Henghe Pharmaceutical Company Limited. The Company's Principal Activities Are The Research, Development, Manufacture And Sale of Medicinal Raw Materials, Medicine Intermediates, Chinese And West

Jinling Pharmaceutical Company Limited. The Group's Principal Activities Are The Manufacture And Sale of Chinese And Western Medicines, Medicinal Raw Materials And Preparations And Biological And Chemical Products. Other Activities Include The Manufacture

Jiuzhitang Company Limited Formerly Known as Hunan Jiuzhitang Company Limited. The Group's Principal Activities Are The Development, Manufacture, Wholesale And Retail of Chinese Medicines, Chinese Medicinal Materials, Western Medicines, Biological Pharmac

Jiwa Bio-Pharm Holdings Ltd. The Group's principal activities are research, development, manufacture and sale of pharmaceutical products. Other activities include trading of health care products and investment holding. Operations are carried out in Hong Kong, the British Virgin Islands and the People's Republic of China. Pharmaceutical products accounted for 70% of fis 2006 revenues; trading, 25% and health care products, 5%

Johnson & Johnson. The Group's principal activity is to manufacture and market products in the health care field. The Consumer segment manufactures and markets a broad range of products used in the baby and child care, skin care, oral and wound care and women's health care fields. The Pharmaceutical segment provides franchises in the antifungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, psychotropic and urology fields. The Medical Devices and Diagnostics segment includes products used by or under the direction of physicians, nurses, therapists, hospitals, di

Jones Pharma Incorporated manufactures, markets and distributes specialty pharmaceutical products. The company's product lines consist of thyroid treatment products related to the endocrine therapy. These include levothyroxine, liothyronine and methimazole. The other products are thrombin which is used as hemostatic agent and methohexital which is used as a general anesthetic agent in the critical care market. Major customers for the company's products include McKesson HBOC, INc., Bergen Brunswig Corp., Cardial Health, Inc. and other wholesalers. The company has incurred 1.5 million dollars to

K-V Pharmaceutical Company. The Group's Principal Activities Are to Develop, Acquire, Manufacture And Market Technologically Distinguished Branded And Generic Prescription Pharmaceutical Products. The Group Also Develops, Manufactures And Markets Raw Mate

PROVIDES NON-RADIOACTIVE DIAGNOSTIC PRODUCTS AND LABORATORY ANALYSIS SERVICES TO RESEARCH FACILITIES & HOSPITALS

Keun Wha Pharmaceutical Company Limited. The Company's principal activity is the manufacture of pharmaceutical products. Brand names include Somalgen and Kalimate.

Korea Schnell Pharmaceutical Company Limited. The Company's principal activity is manufacturing medicinal medicaments. Products include lactarmox, capsule 300C, ainaminju and easylong Internal medicine. Lactarmox acctd for 27% of fiscal 2006 revenues; Capsule 300C, 7%; Ainaminju, 6%, easylong internal medicine, 6% and other, 54%

Krka DD Novo Mesto. The Group's principal activities are the manufacture and sales of pharmaceutical and cosmetic products. The range includes prescription pharmaceuticals, self-medication products, animal health products and cosmetics. The Group sells approximately one-fifth of its production in the domestic country and the rest is marketed in 70 countries worldwide.

Kukje Pharm Industrial Company Limited. The Company's principal activity is the manufacturing, importing, exporting, marketing and distributing of pharmaceuticals, cosmetics and health care products. Brand names include Arofen Tab, Lipecor, Kukje Atenol, Kukje Cepotetan, Axadin, Lebotal Tab, Kemoshin Tab, Peptiraje Tab, Tarabutine Tab, Propa Tab, Campicil Tab, Potacin Tab, Potacin Syr, Kukje Cefadroxil Cap, Tricef cap, Tricef Inj, Cetezole Inj, Kukje Cefazedone Inj, Kemocin Dry syr, cap and others.

Kunming Pharmaceutical Group Ltd.. The Group's principal activities are the manufacture and sale of pharmaceutical products. Other activities include distribution of purchased medicine from other manufacturer. Main products include chemical synthesized medicine and natural plants extract medicine. Operations are carried out in the People's Republic of China.

Kyto Biopharma, Inc.. The Group's principal activity is to acquire a patent portfolio and the rights to early-stage compounds which have potential use as therapeutic agents for the treatment of cancer and diseases of the immune system. The Group subsequently built itself into a development stage biopharmaceutical company that develops receptor-mediated technologies to control the uptake of vitamin B12 by non-controlled proliferative cells. Vitamin B12 regulates one of two major cellular pathways for the production of folates, the cell's primary source of carbon and the progenitor for the synth

Lab International Inc. The Group's Principal Activities Are to Develop And Manufacture Innovative Therapeutic Products. The Group Operates in Three Business Segments: Research Services, Pharma And Corporate. Research Services Provide Drug Development Serv

Laboratoire Pharmygiene Medipole produces medicinal products including external anti-parasitic medicines, family medication, veterinary medication, hospital and laboratory products. It also operates in cosmetics including make-up, sun protection and skin care products for babies. The company became publicly held in July 1998. Pharmygiene Medipole operates in Belgium in addition to France and exports to 80 countries. In 1998, the group acquired Laboratoire Thekane which specialises in veterinary products. Medicine accounted for 51% of fiscal 1999 revenues and cosmetics and skin care products, 4

Laboratoires Arkopharma SA(ARKOPHARMA). The Group's principal activity is to manufacture medicines from plant extracts. It operates in the following areas: Phytotherapy which manufacture drugs used for fatigue, circulation, slimming, insomnia, stress, beauty treatments for dermal appendages and urinary problems. They also manufacture tobacco & nicotine free cigarettes. Nutrition Therapy deals with diet products, vitamins, minerals and other dietary supplements. Skin Care deals with plant-derived products for skin care and treatment such as sun-screens creams and treatment for acne and hair los

Lannett Company, Inc.. The Group's principal activities are to develop, manufacture, package, market and distribute pharmaceutical products sold under generic chemical names. The Group manufactures and sells a line of both prescription and over-the-counter drug products. Trademarks include Diamox(R), Lioresal(R), Fiorinal(R), Cleocin(R), Danocrine(R), Periostat(R), and Dilaudid(R). The Group's products are used in the treatment of migraine headaches, heart failure, Hormone Replacement, epilepsy, Muscle Relaxer, Dryness of the Mouth, diarrhea, thyroid deficiency and Pain Management. It sells it

Fermenta AB researches, manufactures and markets veterinary products including antibiotics, insecticides and anthelmintics; also involved in the wholesale distribution of pharmaceuticals in several of the most important therapeutic areas and products for the poultry, equine and companion animal markets. Trademarks include CSP-250, Denagard, Patriot, Doxyferm and Pollyferm. The company Independent AB was sold in 1992 and real estate operations were sold in 1993. The company operates in Europe, North America, Asia and other countries. Veterinary products accounted for 96% of 1993 revenues and wh

Leciva a.s.. Leciva a.s. is a joint stock company which produces and markets drugs and cosmetics. The company also manufactures packaging materials for pharmaceutical products and single purpose equipment and machines for the pharmaceutical industry. During 1998 the company concentrated on developing human insulins. Leciva publishes a monthly magazine - QALT (Quality and You). The company incorporates two sales divisions: domestic (including Slovakia) and export sales. The majority of the company's products are sold in the Czech Republic, Slovakia, Russia, Poland, Belorus and Transcaucasia inc

MANUFACTURES AND MARKETS VITAMINS, MINERALS AND NUTRITIONAL SUPPLEMENTS. SALES BREAKDOWN NOT AVAILABLE

Les Trois Chenes. The Company's principal activities are the development, production and marketing of dietary and cosmetic products. The activities are concentrated in the areas of beauty, weight-loss, nutrition, circulation, relaxation and massage, vitamin supplements and natural energy products. These products include a hair health and colouring range ("COLOR&SOIN"), a skin hygiene product ("NOAKNE") and an anti-ageing product ("CONCENTRE JEUNESSE"). The Company distributes theses products to over 40 countries worldwide.

Lipa Pharmaceuticals Ltd. The Company's Principal Activity is The Manufacturing And Distribution of Pharmaceutical Products. These Products Include Herbal Medicines, Vitamins And Nutritional Supplements. It Also Produces Non-Sterile, Over-The-Counter Medi

LXR Biotechnology Inc. is a development stage company. The company engaged in the research and development of therapeutics to treat diseases caused by or associated with apoptosis. Apoptosis is a form of cell death that occurs in a timely and atraumatic fashion. The company mainly focusses towards developing of Elirex. Elirex is a project involving compounds that prevent or reduce tissue damage following heart attack and strokes. The company is presently working on a number of long-term development projects that involve experimental and unproven technology. Funded research accounted for 70% of

MANUFACTURES AND MARKETS A BROAD LINE OF INJECTABLE THERAPEUTIC DRUGS FOR CRITICAL CARE PATIENTS

Mannkind Corporation. The Group's principal activity is to discover, develop and commercialize therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. Its lead product, Technosphere Insulin System, currently in late Phase II clinical trials consists of a proprietary dry powder Technosphere (R) formulation of insulin for the treatment of diabetes. The Group also develops additional applications for its proprietary Technosphere formulation technology and develops therapies for the treatment of solid-tumor cancers. Technosphere(R) and MedTone(R) is the re

Marion Merrell Dow, Inc. is involved in the business of discovering, developing, manufacturing and marketing parmaceutical products & products for hospital use. The major pharmaceutical products include Cardizem, Cardizem CD, Cardizem SR, Seldane & Seldane-D and other important drugs include Carafate, Nicoderm & Nicorette chewing gum. These products are marketed through programs targeted to reach medical and healthcare professionals in the U.S. and worldwide.

Marketing Systems of America Inc manufactures, packages and markets certain generic drugs, health care and beauty products through its subsidiaries Custom Packaging Services Inc and Skin Research Laboratories Inc. The pharmaceuticals and cosmetics are produced in liquid or powder form, encapsulated when required and then inserted into bottles or foil packets, sealed packaged, labeled and shipped to customers. The company is currently developing new products through two wholly owned subsidiaries Body Zone Enterprises Inc and Beres Drops USA Inc.

Marshall Edwards, Inc.. The Group's principal activities are to develop and commercialize drugs for the treatment of cancer. The Group is presently involved in the clinical developments of the anti-cancer drug Phenoxodiol. The Group has been formed to commercialize new family of chemicals known as Multiple Signal Transduction Regulators (MSTRs). The Group is in its development stage and phase II trials of the drug Phenoxodiol. The Phenoxodiol appears to target a number of key components involved in cancer cell survival and proliferation with little or no effect on normal cells based on the eme

Matrix Laboratories Limited. The Group's principal activity is to manufacture active pharmaceutical ingredients and intermediates. Its products are used in anti-bacterial, anti-fungal, CNS, gastrointestinal, anti-retroviral, anti-virals, anti-depressant and cardiovascular segments. The Group markets and exports its products in Europe, India, United States of America, Africa, SouthEast Asia and other countries. Pharmaceuticals accounted for 86% of fis 2006 gross revenues and Medical Supplies, 14%

Maxim Pharmaceuticals, Inc.. The Group's principal activity is to develop and offer drug candidates for life-threatening cancers, hepatitis C and other chronic liver diseases. The Group's leading drug candidate is Ceplene TM designed to prevent or reverse damage associated with oxidative stress, thereby protecting immune cells and other critical cells and tissue. Clinical trials of Ceplene have been conducted for advanced metastatic melanoma, acute myelogenous leukemia, renal cell carcinoma and hepatitis C. The Group has also developed and is employing a proprietary high-throughput screening s

The leading supplier of integrated pharmacy management systems and services.

Med Gen, Inc.. The Company's Principal Activity is to Manufacture, Market And License Healthcare Products, Specifically to The Market For Alternative Therapies (health Self-Care). The Products of The Company Are Snorenz (tm), Good Nights Sleep (tm), 4-in-

Meda Ab. The Group's principal activity is the marketing and sales of pharmaceutical products, self-medication products, medical devices, anaesthetic and nutrition products. The Group operates three segments: Pharma, Medical device and Parallel trading. The Pharma segment markets its own licensed drugs in the therapeutic areas of pain/inflammation. gastroenterology, cardiology/diabetes and odontology. The Medical device segment sustains the Pharma business area in terms of finance and know-how. Parallel trading means that products are purchased from a wholesaler in European country and sold in

Medco Research, Inc., is engaged in the research and development of pharmaceutical products, primarily on the diagnosis and treatment of cardiovascular disease. The company acquires products which have already undergone some preclinical and clinical testing. The company sponsors and directs additional preclinical studies and clinical testing needed for product registration and marketing approval. Adenocard, Adenoscan, Medr-640, Viascint, Glucarate, Bidil, Adenosine triphosphate are some of the products of the company.

Medec Ltd. The Group's Principal Activities Are The Manufacture of Health Care Products And The Distribution And Marketing Network For Marketing of Goods. At 02-01-2004, The Group Acquired a 100% Interest in Athlegen Pty Ltd, a Wholesale Manufacturer, Dis

Medeva PLC is an international prescription pharmaceutical company with subsidiaries in the UK, USA, France, Spain, Belgium and the Republic of Ireland. It develops, manufactures and sells prescription pharmaceutical products, principally in the following areas: central nervous system, respiratory diseases, adult and paediatric vaccines, hospital products, attention deficit disorders, anaesthesia, critical care and pain management, dermatology and gastro-intestinal diseases. Medeva plc is actively involved in research for AIDS, cancer and other viral infections.

Medeva PLC is an international prescription pharmaceutical company with subsidiaries in the UK, USA, France, Spain, Belgium and the Republic of Ireland. It develops, manufactures and sells prescription pharmaceutical products, principally in the following areas: central nervous system, respiratory diseases, adult and paediatric vaccines, hospital products, attention deficit disorders, anaesthesia, critical care and pain management, dermatology and gastro-intestinal diseases. Medeva plc is actively involved in research for AIDS, cancer and other viral infections.

Medical & Biological Laboratories Co Ltd(MBL). The Group's principal activity is to research, develop and manufacture clinical reagents and basic research reagents. The Group sells these products to hospitals, clinical testing centers and research institutions. The Group also handles purchased products, related equipment and instruments. The operations are carried out through the following divisions: Basic Research and Bio Related Business.

Medical Developments International Ltd. The Company's Principal Activities Are The Manufacture And Distribution of a Pharmaceutical Drug And Medical And Veterinary Equipment.

Medicis Pharmaceutical Corporation. The Group's principal activities are to develop and market products for the treatment of dermatological, aesthetic and podiatric conditions. The Group offers various products addressing various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis. The major brands of the Group includes OMNICEF(R), RESTYLANE(R), SOLODYN(R),TRIAZ(R), VANOSTM Cream 0.1%, and ZIANATM Gel. The products are sold primarily to

A DEVELOPMENT STAGE COMPANY ORGANIZED TORESEARCH, DEVELOP, TEST AND COMMERCIALLY EXPLOIT ANTI-INFECTIVE DRUGS

Medizone International Inc. The Group's principal activity is to develop, promote and distribute ozone-generating equipment and related products for medical applications. It is in its development stage. The Group is seeking regulatory approval for the drug called MEDIZONE(R), which is a precise mixture of ozone and oxygen. The drug can be used as a therapeutic drug in humans to inactivate certain viruses and to treat certain viral diseases including AIDS-related virus, Hepatitis B, Hepatitis C, Epstein-Barr, herpes, cytomegalovirus and to decontaminate blood and blood products. The Group owns

Collection of materials in the major areas of the health sciences and in chemistry, physics, botany and zoology.

Memory Pharmaceuticals Corporation. The Company's principal activities are to research and develop innovative drug candidates. The Innovative drug candidates are used for the treatment of central nervous system conditions that exhibit impairment of memory and other cognitive functions. The central nervous system therapies are designed to address biological targets within the cellular pathways. These are involved in memory formation and other cognitive functions. It currently has four clinical and preclinical drug candidates and also multiple drug discovery programs in development. These drugs

Menley & James Inc. produces and markets pharmaceutical and toiletry products. These products are sold to drug stores, supermarkets and other merchandisers throughout the United States. The company had an arry of 35 brands as of 1998. During November 1998, the company sold itself to Numark Laboratories, Inc. As of december 1998, the company had no operating business.

Merck & Co. , Inc.. The Group's principal activity is to develop, manufacture and market a broad range of innovative products to improve human and animal health. The products of the Group are sold primarily to drug wholesalers and retailers, hospitals, clinics, government agencies and health care providers such as health maintenance organizations and other institutions. Some of the important products of the Group include Arcoxia, Cancidas, Comvax, Cosopt, Cozaar, Crixivan, Emend, Fosamax, Hyzaar, Invanz, Maxalt, PedvaxHIB, Primaxin, Propecia, Proscar, Recombivax HB, Singulair, Timoptic-XE , Tr

Merck AG manufactures and distributes a braod range of pharmaceutical, chemical and laboratory products, including: preparations for cardio-vascular, central and peripheral systems and gastric complaints, colouring pigments, industrial chemicals and laboratory analysis systems. The company is situated in Zug and is the management and finance company for a group of companies belonging to E. Merck, the German pharmaceuticals and chemicals group. The development & worldwide distribution of pharmaceuticals accounted for 42% of 1994 revenues; laboratory preparations, 32% and chemicals (fine, indust

Merind Limited manufactures and markets pharmaceutical products including elixirs, sterlite solutions, tablets, antibiotics, capsules and ointments, chemicals and diagnostic kits. The company has its manufacturing plant at Mumbai. Pharmaceutical products accounted for 77% of fiscal 1997 gross revenues; chemicals, 20% and diagnostic kits, 3%.

Metabasis Therapeutics Inc. The Group's principal activity is to discover, develop and commercialize novel small molecule drugs principally to treat metabolic diseases. The product candidates in clinical trials are CS-917, remofovir and MB07133, indicated for the treatment of type 2 diabetes, hepatitis B and primary liver cancer, respectively. It also have research programs focused on metabolic diseases linked to pathways in the liver such as type 2 diabetes, hyperlipidemia and obesity, as well as liver diseases such as hepatitis C and liver fibrosis. The CS-917 is being developed in collabora

Myogen, Inc.. The Company's principal activity is to develop and commercialize small molecule therapeutics for the treatment of cardiovascular disorders. It has two selective oral endothelin receptor antagonist (ERA) product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of uncontrolled hypertension. Its product candidates are orally administered small molecules that offer advantages over available therapies. The Company operates in the United States. Discovers, develops and sells therapeutic drug

A national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information.

Information resource for research and education.

Natraceutical SA. The Group's principal activity is the manufacture & sale of nutraceutical ingredients for functional food, cosmetics and pharmaceuticals aimed at preventing diseases & improving the quality of life. The Group operates through a global commercial network and has permanent presence in Europe and American countries. The Group acquired Braes Group in May, 2005. Involved in the manufacture and sale of nutraceutical ingredients, refined butter and caffein

Naturade, Inc.. The Group's principal activity is to market scientifically supported natural products formulated to improve the health and well being of consumers. The Group's products include Naturade Total Soy, a full line of nutritionally complete meal replacements available in several flavours of powders, ready-to-drink products and bars, Naturade Soy protein boosters, Aloe Vera 80 health, beauty care products and other niche dietary supplements. These products are sold to supermarkets, club stores, drug stores, health food stores, natural food supermarkets and the military. These products

Naturewell, Inc.. The Group's principal activities are to develop, manufacture and market health care products and provide certain laboratory services. The Group has two divisions namely healthcare products division and diagnostic division. The healthcare division prepares healthcare and nutraceutical solutions which are used for eye and nose. The diagnostic division develops and markets clinical diagnostic products using immunology and molecular biologic technologies. The Group's primary focus is on the distribution and sale of its migraine medication for prevention of migraine headaches. The

Neurologix, Inc.. The Group's principal activity is to conduct research and development of treatments for disorders of the brain and central nervous system utilizing gene therapies. These treatments are designed as alternatives to conventional surgical and pharmacological treatments. The Group focuses on gene therapy products for treating Parkinson's disease and, more recently, epilepsy .The Group's core gene therapy technology NLX, is currently being tested in a Phase I human clinical trial, to treat Parkinson's disease. A Phase I clinical trial is designed to test the safety, as opposed to e

Neuromedical Systems, Inc. a development stage company develops, manufactures and markets systems for computer assisted screening of pap smears and other cytological specimans. The company's product papnet testing system is used in laboratories in detection of abnormal cells on pap smears. Papnet is also used in detection of bladder and lung cancer. During the year, the company acquired New System International, Ltd. The company has international operations in Europe, Israel, Asia and Australia.

New River Pharmaceuticals Inc.. The Group's principal activity is to develop safer and improved versions of widely prescribed drugs in large and growing markets. Utilizing proprietary Carrierwave technology, the Group develops novel pharmaceuticals to address the significant drawbacks and adverse side effects of currently marketed drugs. The Group's Carrierwave technology can be applied in various ways to improve existing drugs. The Group is in the development of three lead product candidates. The first product is NRP104, which is a prodrug of amphetamine. NRP290, the second product candidate,

NeXstar Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company. The company discovers, develops, tests, manufactures and markets proprietary medical drugs. The drugs are used in the treatment of life-threatening and other serious diseases. The main product AmBisome, is an antifungal agent. The second product, DaunoXome is an approved primary therapy for Kaposi's sarcoma. The third product, MiKasome, a treatment for multiple drug resistant tuberculosis, is undergoing clinical trials. Growth strategy for the future includes various strategic collaborative partnerships in the areas

Nikken Chemicals Co Ltd. The Company's principal activities are the development, manufacture and sale of a wide range of pharmaceutical products which include advanced cardiovascular agents, respiratory agents, growth hormones, transfusion fluids and other prescription drug. The Pharmaceuticals division deals with anthine bronchodilator, serum potassium level suppressant, oral disaccharide preparation, acetate fluids, acetate maintenance solution and anti-epileptic agents. The Company's principal activities are the development, manufacture and sale of a wide range of pharmaceutical products

Nissui Pharmaceutical Co., Ltd.. The Group's principal activities are to manufacture clinical reagents for the medical profession and over-the-counter drugs for the public. The Group is also into wholesale of medical instruments, appliances and other bought-in products. The operations are carried out through the following divisions: Reagents and Pharmaceuticals. Pharmaceuticals accounted for 52% of fiscal 2006 revenues and reagents, 48%

Nitromed, Inc.. The Group's principal activities are to research, develop and commercialize proprietary pharmaceuticals based on naturally occurring molecule nitric oxide. The Group uses nitric oxide technology to develop new pharmaceuticals, as well as safer and more effective versions of existing pharmaceuticals to target diseases and commercial markets. Nitric oxide is a naturally occurring compound that is synthesized in cells to regulate a broad range of cellular reactions which benefits heart failure, pulmonary hypertension and sexual dysfunction. In June 2005, BiDil was approved by the

Northeast Pharmaceutical Group Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Chemical Biological Preparations, Medicine Raw Materials, Sanitation Materials And Medicine-Making Equipment And Fittings. Other Activities Include

Novartis AG. The Group's principal activity is the development and manufacture of pharmaceuticals and nutritional products. The Group operates through four divisions; Pharmaceuticals, Consumer Health, Sandoz & Vaccines & Diagnostics. Pharmaceuticals Division includes drugs for use in transplantations, central nervous system disorders, cardiovascular, endocrine and respiratory diseases, dermatology, oncology, hematology and rheumatism and bone and hormone replacement therapy. Consumer Health Division includes Generics/OTC and sells copies of prescription medicines no longer under patent protect

Novogen Limited. The Group's Principal Activities Are Pharmaceutical Research And Development And Manufacturing And Marketing of Health Supplements. It Operates in Australia, New Zealand, North America And Europe.

Nutracea. The Group's principal activities are to develop and distribute various products based upon the use of stabilized rice bran and proprietary rice bran formulations. These products include various health food supplements and cosmetic and beauty aids. The Group also develops and markets rice bran food supplements for animals. The activities of the Group are carried out through four divisions: TheraFoods, NutraCeal, NutraGlo, and NutraBeauticals. The TheraFoods division consists of the sale of consumer products such as RiSolubles(R), RiceMucil(R), NutraFlex(TM), and StaBran(R). The NutraC

MANUFACTURES HEALTH CARE PRODUCTS SUCH AS COUGH COLD PRODUCTS, BABY CARE PRODUCTS, OPTHALMICS & PERSONAL CARE PRODUCTS

Nutrition 21, Inc.. The Group's principal activity is to develop and market innovative chromium based nutrition products for use in improving the structure or function of the body. The products are used as Ingredients in nutritional supplements. They include the Chromax (TM) chromium picolinate, a form of the trace mineral chromium. The Group's products are used in age-related health care concerns, including obesity, insulin resistance, diabetes, cardiovascular disease, mental health and joint health. Its major trademarks are Chromax, Diachrome, Selenomax, SelenoPure, Zinmax, Zenergen and Magn

Nycomed ASA is an international pharmaceutical group based in Norway. The company is engaged in the research and development, production, distribution and licensing of medical imaging contrast media and in the development, manufacturing and distribution of a range of prescription and over-the-counter therapeutics and consumer health products. Nycomed ASA's principal product is currently the Omnipaque, which is a non-ionic X-ray contrast medium. Medical diagnostic imaging accounted for 59% of 1996 revenues; pharmaceuticals, 40% and other, 1%.

NYMOX PHARMACEUTICAL IS A DEVELOPMENT STAGE BIOPHARMACEUTICAL COMPANY WITH SEVERAL MAJOR PHARMACEUTICAL PROJECTS IN DEVELPOPMENT

Manufacturer of pharmaceuticals for consumers.

Onco Therapy Science, Inc. The Company's principal activity is to develop, manufacture and sell cancer related gene information, reagents, pharmaceutical and drugs. It is also engaged in the licensing of the development, manufacture and sale of medical products.

Oncor, Inc.. Oncor, Inc. develops, manufactures and markets a variety of molecular biology products, most significantly restriction enzymes and markets related apparatus and equipment. During the year the company acquired remaining outstanding shares of Codon Pharmaceuticals, Inc.. The company also has operations in Europe, Japan and other countries. On February 26, 1999, the company filed voluntary petitions for relief under Chapter 11 of the United States Code. Biotechnology accounted for 96% of 1998 revenues and contract andgrants, 4%.

Manage enterprise-wide operational, safety, environmental, quality, security, and financial risk through continuous process improvement & compliance.

About Us | Demo | Customers | White Papers

DESIGN, DEVELOPMENT & COMMERCIALIZATION OF COST EFFECTIVE THERAPEUTIC & DIAGNOSTIC PRODUCTS FOR HUMAN & ANIMAL USE

Oragenics, Inc.. The Group's principal activities are to develop engineered streptococcus mutans for oral and other therapeutic applications. The Group is a biotechnology company aimed at adding value to novel technologies and products sourced from research performed at the University of Florida and other academic centers. It's aim is to in-license and develop products through human proof-of-concept prior to partnering with major pharmaceutical, biotechnology or healthcare product firms for advanced clinical development and commercialization. Currently, the Group develops products in the areas

Orchid Chemicals & Pharmaceuticals Ltd. The Group's principal activity is to manufacture and sell pharmaceuticals ingredients and finished dosage forms. It has two divisions, namely Bulk and Formulations. The Group manufactures active pharmaceuticals ingredients and is a 100% export-oriented unit. It also manufactures and sells finished dosage forms (formulations) for the domestic and export market. It focuses on the Cephalosporin range of antibiotics. The Group has exports to Asia Pacific, Europe, Middle East, South and Central America, North America and CIS Countries. Manufacture & sell phar

Orlando has over 150 biotech & life science companies with top hospitals, research facilities, & medical equipment vendors. Free report download here.

Oxis International Inc.. The Group's principal activity is to develop research assays, diagnostics, nutraceutical and therapeutic products. It includes new technologies applicable to conditions and diseases associated with oxidative stress. The Group market products and technologies related to oxidative stress. Oxidative stress is associated with an excess of free radicals, reactive oxygen species ("ROS"), and a decrease in antioxidant levels with a resultant development of tissue or organ damage. Oxidative stress can cause tissue injury by triggering cell death or inciting a tissue-damaging i

Pacific Pharmaceutical Co., Ltd.(PACP). The Company's principal activity is manufacturing of medicinal medicaments such as Ketotop, SS Cream and Ramisil Ketotop acctd for 36% of 2005 revs; pantoroc, 8%; taligen, 4%; ramisil, 5%; livital, 2%; leprocshin, 3% and Others, 42%

Pak Fah Yeow International Limited. The Group's Principal Activities Are The Manufacture of Hoe Hin Brand of Products, Property Investment, And Distribution of Healthcare And Household Products.

Canadian specialty pharmaceutical company.

Panacea Biotec Ltd. The Group's principal activities are manufacture and marketing of vaccines, branded formulations and biotechnology-based products. Besides Pain Management, Diabetic Management and Vaccines, the Group has presence in other therapeutic areas, namely, Renal Transplantation, Osteoporosis, Antibacterial Therapy, Tuberculosis, Peptic Ulcers, Cardiac Emergencies, Migraine, Erectile dysfunction & Dietary Supplements. The brand names include Nimulid, Nimulid MD, Nimulid Suspension, Alphadol, Alphadol-C, Glizid, Glizid-40, Glizid-M, Glizid MR, Livoluk, Panimun Bioral & Mycept. Vaccin

Panbio Limited. The Group's Principal Activities Are The Development, Manufacture And Sale of a Range of Medical Diagnostic Kits For Infectious Diseases in Humans And Animals. These Test Kits Are Used by Hospitals, Pathology Laboratories, General Practiti

Par Pharmaceutical Companies, Inc. Formerly known as Pharmaceutical Resources, Inc.. The Group's principal activities are to develop, manufacture and distribute generic drugs and complex synthetic active pharmaceutical ingredients in the United States. The products are in the form of tablet, capsules, and semi-solid and two-piece hard shell capsule. Generic drug consists of 213 products representing various dosage strengths for 92 separate drugs. The Group markets its products to wholesalers, retail drug store chains, managed health care providers, clinics, governmental agencies, health care o

Patch International Inc Formerly Known as Praxis Pharmaceuticals Incorporated Ut. The Group's Principal Activities Are to Develop And Commercialize Non-Prescription Therapeutics And Nutraceutical Drugs Designed to Prevent Inflammation And Their Sequelae A

PathoGenesis Corporation. The principal activities of the Group are the development of drugs to treat chronic infectious diseases where there is a significant need for improved therapy; the market of TOBI (tobramycin solution for inhalation), an inhaled antibiotic; and the development of other drug candidates to treat serious chronic lung infections, including those common in cystic fibrosis, brochiectasis and tuberculosis patients.

Search and find patient assistance programs offered by the pharmaceutical industry. Apply and get free medication if you are approved.

PDK Labs Inc. manufactures and distributes non-prescription pharmaceutical products, vitamins and food supplement products, cosmetics and beauty aids. The products mainly consists of non-prescription pain relievers, decongestants and bronchodialators. They are marketed through direct salespersons, manufacturers representatives and various supply and licensing agreements. The manufacturing equipment used by the company can produce the tablets, package the products and label the containers in one operation. Non-prescription pharmaceutical products accounted for 87% of 1999 revenues and multi-vit

Pfizer Inc.. The Group's principal activities are to discover, develop, manufacture and sell prescription medicines for humans and animals and also healthcare products. The Group operates in three segments: Human Health segment, Consumer Healthcare segment and Animal Health segment. Human Health segment includes treatments for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders and allergies. Consumer Healthcare segment markets medications for oral care,

A community for pharmaceutical manufacturing professionals.

Pharmacia & Upjohn Incorporated. The principal activities of the Group are in the research, development, manufacture and sale of pharmaceutical and healthcare products and divided into two segments namely: (i) Prescription pharmaceutical which includes general therapeutics, ophthalmology and hospital products including oncology, and diversified therapeutics; and (ii) Consumer health care which consists of self-medication products that are available to consumers over the counter without prescriptions, product line extensions of key prescription drugs, plus products to treat tobacco dependency.

89 REVS WERE DERIVED FROM THERAPEUTICS, 33%; BIOTECHNOLOGY, 24%; DIAGNOSTIC, 22%; OPHTHALMICS, 17% & OTHER, 4%

Pharmacia AB, formerly Procordia AB, develops, manufactures and markets pharmaceutical and biotechnological products including therapeutics, oncology and hospital care products, growth hormone preparations, ophthalmics, diagnostics, smoking-cessation and other pharmaceuticals and medical instruments & equipment. Trademarks include Genotropin, Healon, Farmorubicin/Pharmorubicin and Nicorette. In June 1993, Volvo AB and the Swedish state announced that Procordia AB's operations were to demerge into two parts. Food and consumer products were transferred to Volvo AB and Pharmacia AB were to concen

Asterand PLC Formerly known as Pharmagene PLC. The Group's principal activity is human-tissue based research for the pharmaceutical and biotechnology industry. It acquires human tissue samples post surgery and post mortem, subject to strict ethical standards and legal requirements. The Group operates in two businesses in the United Kingdom, Europe, North America and Japan. Drug Discovery Services applies its expertise on a fee-for-service basis for pharmaceutical companies. Therapeutics conducts proprietary research and development for its own portfolio of pharmaceutical compounds to treat hum

Pharmaprint Inc.. Pharmaprint Inc., develops and manufactures pharmaceutical versions of herbal medicines. The PharmaPrint TM process technology developed by the company enables it to identify, quantify and standardise the bioactives within the plant sources. The process identifies and combines the molecules responsible for health benefits and thus replicates the effectiveness of a natural product. These derived therapeutic medicines are herbal supplements to the diet and are the main application of the process. The second application of the PharmaPrint TM Process is to develop natural drugs w

Researcher, developer, manufacturer and marketer of generic and innovative products for both prescription and over the counter sale.

Pharmaxis Ltd. The Group's Principal Activity is The Research, Development And Marketing of Therapeutic Products to Improve The Clinical Management of Chronic Respiratory And Autoimmune Diseases. It is Focused on The Development of Its Two Leading Technol

Photocure ASA. The Group's principal activity is to develop and sell pharmaceuticals and medical devices for the treatment and diagnosis of different types of cancer. The products are based on proprietary photodynamic technologies, targeting specific dermatology and oncology markets. The Group has two pharmaceutical products on the market: Metvix, for the treatment of sun-damaged skin and certain types of skin cancer and Hexvix, for the diagnosis of bladder cancer. The Group has also developed a proprietary light source, the Aktilite lamp, which is used in combination with the Metvix cream. In

Pingchuan Pharmaceutical, Inc. Formerly Known as Xenicent, Incorporated. The Group's Principal Activity is to Produce Antibiotics, Medicine in Capsule Form, Traditional Chinese Medicine And Other Products. The Group Also Produces Medical Intermediates And

RESEARCHES, DEVELOPS, MANUFACTURES, TESTS & DISTRIBUTES BIOLOGICAL PRODUCTS USED TO DIAGNOSE VARIOUS ILLNESS & CONTAMINANTS

Polymasc Pharmaceuticals plc conducts research and licenses products and processes to the pharmaceutical and medical diagnostics industries. The company was admitted to the Alternative Investment Market of the London Stock Exchange in December of 1995.

The Premier Pharmaceutical Company Limited manufactures, markets and distributes pharmaceutical, consumer, visioncare and animal health products. It is a major supplier of ethical, generic and over-the-counter pharmaceutical products for pharmacies, dispensing and prescribing doctors, clinics, hospitals and wholesalers in the private sector. It was founded in 1953 and listed on the Johannesburg Stock Exchange in February 1988. The Premier Group Limited is its majority shareholder with a further substantial holding by the Krok family trusts.

Pressure Biosciences, Inc.. The Group's principal activity is to focus on the development and commercialization of a novel, platform technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. It currently holds holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including areas such as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics and protein purification. The Group owns a 30%

Procyon Corporation. The Group's principal activity is the development and marketing of proprietary medical products used to treat pressure ulcers, dermatitis, inflammation and other skin problems. It operates through its two wholly owned subsidiaries, Amerx Health Care Corp and Sirius Medical Supply. Amerx Health Care Corp develops and markets proprietary medical products used in the treatment of pressure ulcers, dermatitis, inflammation and other skin problems. Sirius Medical Supply operates as a full service mail order medical supply company selling primarily to Medicare and Medicaid custom

Pronova A.S manufactures and markets alginates extracted from kelp and seaweed, fatty acids and esters made from fish oil and pharmaceutical products. The company has extensive long-term research and development projects. Biopolymers accounted for 63% of 1994 revenues; oleochemicals, 24%; biocare products and long-term research, 13%.

Protalex, Inc.. The Company's principal activity is to develop biopharmaceutical drugs used for the treatment of autoimmune and inflammatory diseases. The bioregulatory compounds are based on the principle of normalizing the activities of immune cells at a more basic level than traditional pharmaceutical agents, which act upon the end products of complex metabolic pathways. The Company is in its development stage and currently has no products in the market. Develops biopharmaceutical drugs used for the treatment of autoimmune and inflammatory diseases

Proteo, Inc.. The Group's principal activities are to develop, manufacture, promote and market pharmaceuticals and other biotech products. The Group focuses on the development of pharmaceuticals based on human protein Elafin which naturally occurs in human skin, lungs, and mammary glands. This human protein is useful in the treatment of cardiac infarction, serious injuries caused by accidents, post surgery damage to tissue and complications resulting from organ transplantations. The Group is a development stage Company. Intends to develop, manufacture, promote and market pharmaceuticals and ot

PT Procter & Gamble Indonesia. The Company's principal activities are the manufacture, distribution and importation of pharmaceutical, cosmetic, food and shampoo products. The Company's plant is located in Bekasi, West Java. The key element of the Company's restructuring was the sale of the non-health care division to another P&G affiliated company, PT Procter & Gamble Home Products Indonesia. Operations of the Company are carried out in Indonesia, Asia and other countries. Manufactures, distributes and imports pharmaceutical, cosmetic, food and shampoo products

Qingdao Peloa Company Limited. The Group's Principal Activities Are The Research, Development And Transfer of Biological Pharmaceutical Technology. Other Activities Include Investment in Pharmaceutical Industry And Network; Management of Equity Investment

Questcor Pharmaceuticals, Inc.. The Group's principal activity is to develop and commercialize novel CNS-focused therapeutics which addresses significant unmet medical needs. Its primary product is H.P. Acthar Gel, a natural source adrenocorticotropic hormone (ACTH) which provides prolonged release after intramuscular or subcutaneous injection. H.P. Acthar Gel is indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions. It is in the process of building a development pipeline of additional prescription-only therapeutics, with primary focu

Raggio Di Sole Finanziaria SPA has operations in the commercial, financial services, property and biotechnology sectors. The commercial sector refers specifically to the sale and marketing network of biotechnological products. It provides investment services for the financial sector. The Group companies operating in the property sector are engaged in the management and sale of properties held. The biotechnology sector, headed by Raggio Di Sole Biotecnologie SPA, is involved in the research, development and manufacture of products mainly for the health sector in Italy. Commercial sector activit

Renovis, Inc.. The Group's principal activity is to develop drugs to treat neurological diseases and disorders. It's research and development programmes focus on major medical needs in the areas of pain, trauma, stroke and neurodegenerative diseases. The Group's main product is Cerovive, a drug for acute ischemic stroke. The Group is developing two clinical candidates for the treatment of pain: REN-1654, an oral drug for neuropathic pain in clinical trials and REN-213, an intravenous drug for post-operative pain. It operates in the United States and Europe.In March 2006, Group announced, in co

Rexall Sundown, Inc. develops, manufactures and sells vitamins, nutritional supplements and consumer health products. The company distributes its products using three channels of distribution - sales to retailers, catalog and mail order sales and direct sales through independent distributors. The company has operations in Japan, Hong Kong, Taiwan, South Korea and Mexico. The company operates under various trademarks including Sundown, Rexall and Thompson.

PHARMACEUTICALS , CHEMICALS

Rhone-Poulenc Rorer Inc is a publicly traded, global pharmaceutical company dedicated to the discovery, development and marketing of human pharmaceuticals. Two-thirds of the RPR shares are owned by Rhone-Poulenc S.A. which is structured around several closely related core competencies: life sciences, applied chemistry, specialty chemicals and chemical intermediates. RPR operates in all major markets of the world.

Ribi ImmunoChem Research, Inc. develops biopharmaceutical products that stimulate the immune system to generate natural agents and signals to prevent and treat human diseases. The company researches, develops, produces and markets these products some of which are under investigation by other companies for use as adjuvants. The company also manufactures clinical products and develops processes for the commercial scale production of its compounds. The company's technology is based on potent capacities of certain microbial products to modulate the cytokine cascade in man and other animals. The pr

Roberts Pharmaceutical Corporation. The principal activities of the Group are licensing, acquisition, development and commercialization of post - discovery drugs in selected therapeutic categories which include Cardiovascular, Gynecology, Endocrinology, Urology, Oncology, Hematology and Gastroenterology.

Roche Holding AG(ROCHE). The Group's principal activities are to discover, develop, manufacture and market novel health care solutions. The Group operates through two segments namely Pharmaceuticals and Diagnostics. The Pharmaceuticals division includes prescription and manufacturing of pharmaceutical products. The Pharmaceutical segment has three sub-divisions namely Roche Prescription, Genentech Prescription and Chugai Prescription. Diagnostic segment provides products and services in all fields of medical testing. It also provides reagents and test kits for molecular and cell biology, analy

Roussel-Uclaf SA is a major French manufacturer of healthcare, chemical, animal health, agro-chemical & environmental and related products. Healthcare development programmes include antibiological, cardiovascular systems, immunological & endocrinological research. The company has more than 10,000 patents in force worldwide. Roussel-Uclaf transferred its agro-chemical, hygiene & environmental activities to Hoechst Schering AgrEvo GmBH (Germany) in November 1994. Healthcare products accounted for 76% of 1995 revenues; chemicals, 12%; animal health, 5%; agro-chemicals, hygiene & environment, 4% a

S&P Pharmaceutical Industry Company Limited Formerly known as Qinghai Sunshine & People Pharmaceutical Company Limited. The Group's principal activities are the research, development, manufacture and sale of Chinese and Tibetan medicines and health products. Other activities include the wholesale and retail of Chinese and Western medicines, biological products, medicinal and chemical raw materials, medical apparatus and equipment and daily-use chemicals. The Group's major brand is 'Sanpu' and major products include Chongcaojing (an essence made from Chinese caterpillar fungus), Yiganjian (hepa

Sam Sung Pharmaceutical Industrial Co.. The Company's principal activity is the manufacturing and distribution of medical supplies, non-medicine products, medical goods and foods. It operates 1 factory and 6 domestic branches.

Samil Pharmaceutical Co., Ltd.. The Company's principal activity is the manufacturing of treatment medicines. Products include brufen, polybutine, actified tablets, energen, eye drops and others used in ophthalmology, dentistry and pediatrics. Polybutine acctd for 10% of 2005 revs; energen, 5%; ocuflox, 4%; brufen, 4%; sudafedtap, 4%; actifed 3%; and other, 70%

Samjin Pharmaceutical Company Limited(SJP). The Company's principal activity is the manufacturing of medicinal medicaments such as Geborin, Ostemin and Sepolatam. Geborin accounted for 13% of 2006 revenues; Ostemin, 7%; Sepolatam, 5% and Other, 75%

Sandoz AG based in Basel, researches, develops, manufactures and markets pharmaceuticals (prescription & OTC medicines for endocrinology, asthma, allergies etc.); nutritional products (food-drinks, crispbread); agricultural chemicals (pesticides, herbicides etc.); chemicals, (dyestuffs, pigments etc.); chemicals used in the construction industry & seeds, for both the retail and industrial sectors. Sales are distributed by region in Europe, USA/Canada, Asia, Latin America & Africa/Australia. Pharmaceuticals accounted for 50% of 1995 revenues; nutritional products; 26%; industrial agricultural c

Sanjiu Medical & Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Development, Manufacture And Sale of Medicines, Health Care Products And Medical Apparatus. It is Also Engaged in The Development And Transfer of Medical Technologies And

Sanofi SA (formerly known as Elf-Sanofi SA) is a leading French pharmaceutical company, active in the human healthcare, perfumes & beauty products and bio-activity sectors. It also is involved in bio-industries and research. Human healthcare includes ethical pharmaceuticals and over-the-counter medicines. Beauty product brand names include Yves Rocher, Nina Ricci, Yves Saint Laurent and Oscar de la Renta. Bio-activities include food additives and agro-veterinary products. In 1998 the group launched various medicines such as Aprovel, Plavix, Fraxodi. Human healthcare products accounted for 85%

Savient Pharmaceuticals Inc.. The Group's principal activity is to develop, manufacture and market pharmaceutical products for unmet medical needs in both niche and broader markets segments. Its products are distributed worldwide through a direct sales force in the United States. The Group products are Oxandrin & oxandrolone .Oxandrin is an oral synthetic derivative of testosterone used to promote weight gain following involuntary weight loss related to disease or medical condition. Oxandrin is indicated in the United States as adjunctive therapy to promote weight gain after weight loss follow

Schein Pharmaceutical, Inc. develops, manufactuers, markets and distributes generic pharmaceutical products and a line of specialty branded pharmaceuticals. The company's product line includes both solid dosage and sterile dosage generic product. The brand product group focuses on developing and commercializing proprietary pharmaceutical products in niche therapeutic areas. A significant portion of pharmaceticals are distributed in the United States through wholesale drug distributors and major retail drug store chains. On May 25, the company had entered into a definitive merger agreement with

Schering-Plough Corporation. The Group's principal activity is to discover, develop, manufacture and market advanced drug therapies to meet medical needs. It operates through three reportable segments: Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. Consumer Health Care segment develops, manufactures and markets OTC, foot care and sun care products. Animal Health segment discovers, develops, manufactures and markets animal health products. The Group operates in Europe, Canada, Latin America, Pacific area and Asia. Prescription P

Scolr Pharma, Inc.. The Company's principal activity is to develop and formulate pharmaceutical, over-the-counter and nutritional products utilizing its innovative oral drug delivery technologies. The Company uses its patented Controlled Delivery Technologies (CDT) to develop products and license technology to pharmaceutical and nutritional product companies. The CDT platform consists of three patented drug delivery technologies for prescription drugs, over-the-counter (OTC) products and nutraceuticals. The Company also engaged in development of CDT-based extended release formulations of pseud

Seattle Genetics, Inc.. The Company's principal activity is to develop monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. Its diverse portfolio of product candidates includes SGN-30 and SGN-15 in phase II clinical development and SGN-40 in phase I clinical trials. In addition, it has four product candidates currently in preclinical development, SGN-33, SGN-35, SGN-70, SGN-75 and SGN-17/19. The product candidates are based on three technologies: genetically engineered monoclonal antibodies, monoclonal antibody-drug conjugates (ADCs) and antibody

SEQUUS Pharmaceuticals, Inc. manufactures, develops and distributes pharmaceutical products to treat cancer and infectious diseases. The company's proprietary product are for treatment of life threatening systemic fungal infections. These products are marketed in Russia, Finland, Denmark, Ireland, Singapore and the United Kingdom. Pharmaceutical products accounted for 88% of 1997 revenues & royalties and license fees, 12%.

Drugs in Cardiology, Diabeters, Depression, and Venous disease.

Shaman Pharmaceuticals, Inc.. The Company's first botanical dietary supplements product is Normal Stool Formula, derived from tropical plant sources. The Company's products are used in treatment that relieve diarrhea and endemic mycoses. SB-NSF is a botanical dietary supplement that relieves diarrhea without causing constipation. The Company's customer based communities include: people with HIV/AIDS suffering from chronic diarrhea; travelers to high-risk diarrhea destinations; people with HIV/AIDS exhibiting syndrome X symptoms and the syndrome X population at large.

Shandong Dong-E E-Jiao Co., Ltd.. The Group's Principal Activities Are The Manufacturing And Selling of Chinese Herb Medicines, Traditional Chinese Medicines, Auxiliary Materials For Medicine, Biological Products, Health Products And Genetic Engineering M

Shandong Jintai Group Co., Ltd.. The Group's Principal Activities Are The Research, Manufacture And Sale of Chemical Raw Material Medicines, Chemical Medicinal Preparations, Chinese Medicinal Preparations And Biological Medicines. It is Also Engaged in Th

Shandong Lukang Pharmaceutical. The Company's Principal Activities Are The Manufacture And Distribution of Antibiotic Raw Material Medicines, Antibiotics For Humans, Semi-Synthetic Antibiotics, Veterinary Antibiotics, Biotechnology Products And Antibiotic

Shandong Shanda Wit Science & Technology. The Group's Principal Activities Are The Manufacture And Sale of Biological Pharmaceutical Products And Environmental Protection Equipment. Other Activities Include The Development And Marketing of Computer Softwa

Shanghai Fosun Pharmaceutical (group) Company Limited Formerly Known as Shanghai Fosun Industrial Company Limited. The Group's Principal Activities Are The Manufacture And Sale of Genetic Engineering Medicines, Diagnostic Products, Chinese Prepared Medici

Shanghai Jiaoda Onlly Co., Ltd.. The Group's principal activities are research, development, manufacture and distribution of modern biological, medical products, health supplements, disinfectants, health care products and medical treatment equipment. Other activities include the management and development of real estate, selling agricultural byproducts, meter apparatus, car parts and construction materials, importation of raw materials, machinery, equipment and parts, exportation of finished products and provision of tours and technology consultancy services. It carries 'ONLLY' as its brand na

Shanghai Worldbest Pharmaceuticals Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Pharmaceutical Products. Other Activities Include Production of Chemical Oil, Daily-Used Products, Cosmetics, Soap, Synthetic Detergent, Glyceri

Shanghai Zhongxi Pharm. Co., Ltd.. The Group's Principal Activities Are The Manufacture And Distribution of Pharmaceutical Products, Pharmaceutical Raw Materials And Preparations, Agrochemical Products, Household Hygienic Products, Pesticides And Chemical

Shanxi Central Pharmaceutical International Ltd. The Goup's principal activities are the development, manufacturing and provision of Chinese pharmaceutical products. These products are predominantly medicinal preparations and anti-rheumatoid capsules primarily for the treatment of rheumatoid and arthritic conditions. Other activities include the wholesale and retail of Chinese and Western pharmaceutical products and healthcare products in the People's Republic of China excluding Hong Kong and the operation of Taiyuan City Rheumatoid Hospital. Manufacturing of pharmaceutical products accounted

Shanxi Yabao Pharmaceutical Group Co., Ltd.. The Group's Principal Activities Are The Production And Distribution of Medicine's Raw Materials, Injection, Tablets, Capsule And Various Kinds of Medical Preparation. It Also Sells Health And Sanitary Products

Shenzhen Neptunus Bioengineer. The Group's Principal Activities Are The Manufacture And Distribution of Biochemistry Raw Materials, Reagents And Products Such as Biochemical Drugs, Bioengineering Products, Chinese Medicines And Health Care Products. It is

Shin Poong Pharmaceutical Co., Ltd.. The Company's principal activity is the manufacturing of medicinal medicaments such as western drug, raw materials and regent.

Shire Pharmaceuticals Group Plc. The Group's Principal Activity is The Marketing And Research And Development of Prescription Medicines. The Group Focuses on Three Therapeutic Areas: Central Nervous System, Gastrointestinal And Renal Medicine. Marketed Pr

Sichuan Dikang Sci & Tech Pharma.ind., Ltd.. The Group's Principal Activities Are The Research, Development, Manufacture And Sale of Pharmaceutical Products Namely, External-Used Liquid Preparation, Ointment, Infusion Series, Suppository, Colds Capsule, H

Sichuan Quanxing Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Liquor Products. Major Product is White Wine And Major Brands Include 'quanxing,' 'swellfun' And 'tianhaochen.' The Group Also Produces And Markets Raw Materials

Sicor Incorporated. The Group's principal activities are to develop, manufacture and market pharmaceutical products. The Group evaluates performance resource allocation based on the geographic locations of its business units, which are the United States, Italy, Mexico, Lithuania and Switzerland. The operations in the United States focuses on generic finished dosage injectable pharmaceuticals in the areas of critical care, anesthesiology and oncology. The facilities in Italy and Mexico produce oral, pulmonary, intravenous and topical administration, using both chemical synthesis and fermentatio

Sigma Company Limited. The Group's Principal Activities Are The Manufacture And Wholesale of Pharmaceutical And Allied Products And The Provision of Financial And Other Services to Retail Pharmacists. Pharmaceuticals Includes Contract Manufacture For Aust

Sihuan Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Research, Development, Manufacture And Sale of Biological Medicines, Chinese And Western Medicines, Chinese Medicinal Materials, Health Products, Raw Material Medicines, Medical App

SIIC Medical Science & Technology (Group) Ltd. The Group's principal activities are the manufacture, distribution and sale of Chinese medicine and health supplement products and provides investment holding. In 2002, the Group acquired Xiamen Traditional Chinese Medicine Company Ltd. Manufactures, distributes and sells Chinese medicine and health supplement products and provides investment holding

THERAPEUTIC PRODS ACCT'D FOR 54%/43% OF 1988 SALES/OPTG INCOME; DIAGNOSTIC/ANALYTICAL PRODS 30%/33%; EYE/SKIN CARE PRODS 16%/24%

SmithKline Beecham Plc discovers, develops, manufactures and markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. The company has a large research and development function. Operations are based in the United Kingdom, the United States of America, Continental Europe and elsewhere. During 1998 the group acquired the Romanian Europharm Group, and 29.2% equity interest in Quest Diagnostic in 1999. Pharmaceuticals acc

SmithKline Beecham Plc discovers, develops, manufactures and markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. The company has a large research and development function. Operations are based in the United Kingdom, the United States of America, Continental Europe and elsewhere. During 1998 the group acquired the Romanian Europharm Group, and 29.2% equity interest in Quest Diagnostic in 1999. Pharmaceuticals acc

Southwest Phamaceutical. The Group's Principal Activities Are The Production, Process And Distribution of Chinese And Western Medicine And Biological Products in The Form of Tablets, Powdered Preparation, Injection, Infusion, Capsule, Pellets, Syrup, Liqu

MANUFACTURES AND MARKETS HEALTH CARE PRODUCTS

Manufacturer of prescription and non-prescription dermatological soaps, lotions and creams. Parent/holding company with a high-tech unit that provides pharmaceutical research and development. Products are sold to medical industry.

Sudo Pharmaceutical Industry. The Company's principal activity is the production of pharmaceutical and medicinal chemicals such as Cefaclor, Cephradine and Monoammonium.

Sun Pharmaceuticals Industries Ltd. The Group's principal activities are to formulate, manufacture and distribute pharmaceuticals. The operational facilities of the Group are located in Vapi, Silvassa, Panoli, Ahmednagar and Chennai. The Group has international operations in British Virgin Islands, Russia and Bangladesh. During the year the Group acquired Able Laboratories Ltd. Formulates, manufactures and distributes pharmaceuticals

Sunwin International Neutraceuticals, Inc.. The Group's principal activity is to provide traditional Chinese medicine, organic herbal medicine, nutraceutical products, natural sweetener (beet sugar) and veterinary medicine prepared from organic herbal ingredients. It operates in two segments: Chinese and Animal Medicines and Natural Sweetener. Natural Sweetener segment manufacture and sell, a 100% natural sweetener which is extracted from the leaves of the Stevia rebaudiana plant, a green herb plant of the Aster/Chrysanthemum family. It also purchase and resell finished stevioside product from

Superior Supplements, Inc. manufactures, pack and sells dietary supplement products including vitamins, minerals, herbs and specialty nutritional supplements, in bulk tablet, capsule and powder form. The company also manufactures a variety of products for companies which pack and sell health food, drug, convenience and mass market stores. The company packages certain products in bottled form for PDK Labs Inc.

Synergen Inc. is a biopharmaceutical company that develops and manufactures protein-based pharmaceuticals. The company currently has five products in development which are aimed at treating inflammatory and neurological disorders. The company is currently entering into phase three of clinical trials on two of its products, Antril and ciliary neurotrophic factor. These tests are expected to be completed by the end of 1994. The company is also involved in various joint ventures with other major pharmaceutical companies.

Syntex Corporation is engaged in the research, development, manufacture and sale of pharmaceutical products and diagnostic assay systems. Human pharmaceuticals, animal health and nutritional products accounted for 90%/96% of fiscal 93 revenues/operating income and diagnostic systems, 10%/4%.

Synthelabo SA is a pharmaceutical group which produces and distributes pharmaceuticals and medical devices, especially for cardiovascular, central nervous system and gastroenterology-urology applications. It is the third largest pharmaceutical group in France. The company has investments in most European countries, as well as the U.S., Japan and other countries. In 1998 the group signed two agreements, the first with Pierre Fabre for the marketing of an antidepressant and the second with Mitsubishi Chemical for research and development. Pharmaceuticals accounted for 91% of 1998 revenues; medic

Taro Pharmaceutical Industries Ltd. The Group's principal activities are to develop, manufacture and market prescription and OTC pharmaceutical products, as well as active pharmaceutical ingredients, or APIs, primarily in the United States, Canada and Israel. The Group's main areas of focus include topical creams and ointments, liquids, capsules and tablets mainly in the dermatological, cardiovascular and central nervous system therapeutic categories. Pharmaceuticals accounted for all of 2005 revenues

TCPI, Inc.. The Company manufactures and markets wide range of medical diagnostic products for use in physicians offices, at home and at other healthcare locations. The company conducts research and development and commercializes transdermal and skin permeation enhancers. The products of the Company include test screens for glucose monitoring, cholesterol monitoring, family planning, drugs of abuse, infectious diseases and saliva samplecollector. The Company market various over-the-counter and professional use medical diagnostic products under our HealthCheck brand and on a private label and

Tercica, Inc.. The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. It operates only in United States. Develops and commercializes IncrelexTM for the treatment of short stature and other endocrine di

Therapeutic Antibodies Inc. is in research, development, production and marketing of therapeutic antibodies that provide protection against venoms, drugs, toxins and infectious diseases. The company is a developing stage biopharmaceutical company devoting its efforts and resources to drug discovery and development programs. Systems for the production and purification of polyclonal antibody products are developed by the company. The research activities are conducted by the subsidiaries. The company has incurred dollar 45,000 towards year 2000 expenses till date. Licence revenue accounted for 75

Therasense, Incorproated. The Group's principal activities are to develop, manufacture and market glucose self-monitoring systems that reduce the pain of testing for people with diabetes. The product offered includes a FreeStyle system kit, which is a glucose self monitoring system that measures glucose concentrations from a sample of blood. The FreeStyle system kit includes a FreeStyle meter, FreeStyle test strips, FreeStyle lancing device, FreeStyle lancets, FreeStyle control solution and instruction materials. The Group also develops a continuous glucose monitoring system that utilizes a di

Theravance, Inc.. The Group's principal activity is to discovers, develops and commercialize small molecule medicines. It also serves therapeutic areas that include respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders. The Group solely operates in the United States of America. Discovers, develops and commercializes small molecule medicines

Thermo Bioanalysis Corporation. The principal activities of the Group are to design, manufacture and market life sciences instrumentation, consumables, and information management systems, for use in biochemical research and production, as well as in clinical diagnostics.

Tianjin Tasly Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Manufacture, Process And Sale of Pharmaceutical Products. Other Activities Include Provision of Car Freight Transport Services. Products Include Chinese Medicines, Chemical P

Tianjin Tianyao Pharmaceutical, Ltd.. The Group's Principal Activities Are Manufacturing, Marketing And Exporting Raw Material Medicines, Small Capacity Injections And Medicinal Preparations. Major Products Include Corticosteroids And Cardiovasculars.

Tibet Rhodiola Pharmaceutical Holding Company. The Group's Principal Activities Are The Production And Sale of Rhodiola Series of Pharmaceutical Products. Other Activity Includes The Sale of Natural Medicinal Preparation, Hygienic Health Products And Medi

Tissue Therapies Ltd. The Company's Principal Activity is The Research, Development And Marketing of The Entity's Exclusive International Intellectual Property in Wound Healing, Tissue Regeneration And Cell Culture. It is Involved in The Development of Mo

TL Administration Corporation Formerly known as Twinlab Corporation. The Group's principal activities are to manufacture and market science-based nutritional supplements. The Group's products are sold through health and natural food stores, national and regional drug store chains, supermarkets, mass merchandise retailers, military post exchanges. The Group also develops, manufactures and sells vitamins, minerals and specialty supplements ("VMS"), sports nutrition products and diet and energy products under the Twinlab, Ironman Triathlon, Fuel and other brand names. On 22-May-2002, the Group co

Tokyo Tanabe Co., Ltd. was established in 1921 and is one of the leading pharmaceutical manufacturers in Japan. Digestive agents accounted for 26% of fiscal 1999 revenues; blood and body fluid agents, 25%; circulatory and respiratory agents, 19%; anti-allergic agents, 10%; vitamins and hormones, 6%; epidermal agents and ointments, 6%; anti-tumor and metabolic agents, 3%; food additives, 3%; veterinary drugs, 1%; nervous system agents and other pharmaceutical products and other, 1%. The company is affiliated to Mitsubishi Chemical Corporation which holds 25.06% of issued stock.

Topsun Science And Technology. The Group's principal activities are the research, manufacture and sale of pharmaceutical products. Other activities include the provision of design, production and release of advertising services. Pharmaceutical products consist of Chinese and Western medicines and its materials, tablets, soft and hard capsules, pills, injection, infusion and syrups.

ALCOHOLIC BEVERAGE AND PHARMACEUTICAL MANUFACTURE. NO SALES BREAKDONW AVAILABLE

Transcend Therapeutics, Inc. is a developing novel pharmaceuticals which focus on the treatment of diseases associated with oxidative stress and resultant tissue damage. The company develops Procysteine, an intracellular glutathione repleting agent, for the treatment of acute respiratory distress syndrome. The company is developing small molecule, intracellular glutathione-repleting agent designed to limit or prevent oxidative tissue damage. During the year, company ceased all of its developmental activities on recommendation received from an independent Safety Monitoring Board.

Transition Therapeutics, Inc.. The Group's Principal Activities Are to Develop Novel Approaches And Therapeutics For The Treatment of Diabetes, Multiple Sclerosis (ms) And Restenosis. The Group Has Three Technologies That Provide Therapeutic Benefits in M

Tsinghua Unisplendour Guhan Bio-Pharmacy. The Group's Principal Activities Are The Research, Development, Manufacture And Sale of Traditional Chinese Medicines, Western Medicinal Preparations, Biological Medicaments And Health Beverages. It Operates Three

Manufacturers of AIGISRx, an anti-bacterial, surgical mesh envelope designed to prevent pacemaker and defibrillator pocket infections.

Unichem Laboratories. The Group's principal activities are to manufacture and market pharmaceutical formulations, bulk drugs and drug intermediates (human and veterinary healthcare). Manufactures and markets pharmaceutical formulations, bulk drugs and drug intermediates

Unimed Pharmaceuticals, Inc., develops and markets prescription pharmaceutical products in specialty pharmaceutical markets. The company currently promotes three approved drugs namely Marinol, Maxaquin, and Anadrol and is developing others targeted for the HIV/AIDS, endocrinology, infectious diseases and urology markets. Marinol, is an appetite stimulant and antiemetic drug. Maxaquin is a flouroquinolone anti-defective used in urology and infectious disease markets. Anadrol is an orally active anabolic androgenic steroid used to treat various anemias. It also licenses and develops drugs that h

The Upjohn Co serves the world's health & nutritional needs by discovering, developing, manufacturing & marketing human pharmaceuticals, pharmaceutical & specialty chemicals, & animal health pharmaceutical. It has research, manufacturing, sales & distribution in more than 200 locations worldwide and its international business contributes 44% of the total sales. In 1994 the company sold Asgrow Seed Company and its chicken-breeding joint venture.

Valeant Pharmaceuticals International. and non-prescription pharmaceuticals. These pharmaceutical products treat infectious disease, diseases of the skin, neuromuscular disorders, cancer, cardiovascular disease, diabetes and psychiatric disorders. The Pharmaceuticals group produces and markets a variety of pharmaceutical products worldwide. It derives royalty revenue from the sale of Ribavirin by Schering-Plough Ltd. The Group has 430 branded products with 2,350 stock keeping units. The Group markets its products in North America, Latin America, Europe and Asia. On 01-Mar-2005, the Group acqui

Vaso Active Pharmaceuticals, Inc.. The Group's principal activity is to develop, manufacture and market pharmaceutical products. The Group focuses on vaso active lipid encapsulated or VALE, transdermal delivery technology drugs. Currently, we market Athlete's Relief and Osteon in the United States. The Group's products include Analgesics, Toenail fungal treatment, Acne, First aid, Hand and body lotion and Psoriasis treatment. The Group is planning to rebrand the deFEET athlete's foot anti-fungal medication product as Termin8 and Xtinguish. Develops, manufactures and markets pharmaceutical prod

Venturepharm Laboratories Ltd. The Group's principal activities are provision of technology transfer, pharmaceutical development and clinical research services. These involves various steps of drug development processes. Operations are carried out mainly in the People's Republic of China.

Versatech, Inc.. The Group's principal activity is to explore new business opportunities. Previously, the Group manufactured, marketed and distributed hGH Unitropin product. Exploring new business opportunities

Veterin SA. The Company's principal activities concern the operation in the fields of production and distribution of veterinary pharmaceuticals and nutritional supplements, distribution of pet food, pet accessories, as well as distribution of agrochemicals, seeds, chemicals and pisciculture products. The Company's principal activities concern the operation in the fields of production and distribution of veterinary pharmaceutic

Virbac Corporation. The Group's principal activity is to manufacture, market, distribute and sell a variety of pet and companion animal health products. It operates in three segments: Veterinary, Consumer Brands and PM Resources. The Veterinary segment provides animal health products to veterinary clinics throughout North America. The Consumer Brand segment, which sells over-the-counter products for companion animal health to national accounts, distributors and wholesalers and the Contract Manufacturing segment which offers a broad range of services and manufactures highly regulated animal hea

Vitro Diagnostics, Inc.. The Company's principal activity is develop, manufacture and market products for use in research and related applications and developing Therapeutic products. During 2005 it focus on research involving the establishment and characterization of stem cell lines with applications in diabetes research, drug discovery and the development of novel cell therapies for diabetes. The products are envisioned to treat infertility, consisting of injectible purified urofollitropin. They include VITROPIN (TM), VITROPIN-C (TM) and VITROJECT (TM). The Company is also developing technol

Walgreen Co. The Group's principal activity is to operate a chain of retail drugstores that sells prescription and nonprescription drugs. These drugstores also carry additional product lines like general merchandise. They include cosmetics, toiletries, household items, food beverages and photofinishing. Customer prescription purchases can be made at the drugstores as well as through the mail, by telephone and on the Internet. The Group markets its products under various trademarks and trade names and holds assorted business licenses (pharmacy, occupational, liquor etc.) having various lives. A

Warner-Lambert Company manufactures and markets pharmaceuticals, consumer health care products and confectionery. The pharmaceutical products include ethical pharmaceuticals, biological products and hard-gelatine capsules. The ethical pharmaceuticals and biological products are marked under the trademarks and trade names of Parke-Davis and Goedecke. These products are sold to health care professionals. The consumer health products include over-the-counter health care products, shaving and pet care products. Consumer health products include a wide range of products like oral care mouthwash/dent

Wellcome Pakistan Limited whose holding company is Burroughs Wellcome International Limited is involved in the manufacture and sale of pharmaceutical and animal health products. The company launched three new products, "Lamictal" , "Nemazole Tablets and Exosurf" during 1995.

Wellcome plc is an international pharmaceutical group with subsidiaries throughout the world engaged in researching, developing, manufacturing and marketing a wide range of medicinal products. Prescription medicines, including antivirals such as "Zovirax" and "Retrovir", accounted for 92% of 1994 revenues and non-prescription, over-the-counter medicines, 8%.

Wex Pharmaceuticals Incorporated Formerly Known as International Wex Technologies, Inc.. The Group's Principal Activity is to Develop, Manufacture And Sell Pharmaceutical Products For Pain Management. The Pain Management Solutions Are Provided Through Its

Whanin Pharmaceutical Company Limited(WIP). The Company's principal activity is the manufacturing of and development of pharmaceutical preparations including ulcer treatments, antibiotics and tranquilizers. The Company's products include Psychotherapeutics, Osteoporosis treatment, Antiinflammatory Analgesics, Gastro-intestinal Drugs, Antimicrobials, Multi-vitamins and Nutrients, Topicals and Cardio-vascular Drugs. Psychotherapeutics acctd for 60% of fis 2005 rev; Alend tab, 12%; Cycle org tab, 9%; Digest, 5%; Antiphlogistic, 5% & Others, 9%

Wuhan Humanwell Hi-Tech Industry. The Group's Principal Activities Are The Research, Manufacture And Sale of Pharmaceutical And Reproductive Health Care Products. Other Activities Include Development And Sale of Properties, Provision of Environmental Prot

Wuhan Mayinglong Pharmaceutical Group Stock Co.,ltd. The Group's Principal Activities Are The Manufacture And Sale of Chinese Medicines.

Wuhan Spring Biological Engineering Co Ltd. The Group's Principal Activities Are The Research, Production And Sale of Medicine.

Wyeth Ltd. The Group's principal activities are to manufacture and market pharmaceuticals. The Group operates in two segments: Pharmaceuticals and Other. The Pharmaceuticals segment comprise of bulk drugs, oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The Other segment comprise of OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products. The Group operates in India. Its manufacturing plant is located at Verna in Goa. Pharmaceuticals accounted for 88% of fiscal 2006 gross revenues and Other, 12%

Xenometrix, Inc. is a biotechnology company with gene-profiling system designed to characterize the cells' response to pharmaceutical compounds and other chemicals. The company's gene response profiling systems improve the effectiveness of drug discovery and development for the pharmaceutical industry and the manufacture of chemicals used in the production of many commodities. Xenometrix genetically engineers living cells with gene promoters that enable researchers to quantify the level of gene expression when the cells are exposed to chemicals and other agents like ultraviolet light. This pro

Xinjiang International Industry, Ltd.. The Group's Principal Activities Are Developing, Selling And Leasing Real Estate, Principally in Urumqi City. It is Also Engaged in The Research, Development, Manufacture, Process And Sale of Ephedrine Products And D

XTL BIopharmaceuticals Limited. The Group's principal activity is the acquisition, development and commercialization of therapeutics for the treatment of neurophatic pain and, Hepatitis C. The Company is a development stage biotechnology company. It does not yet have any product sales and expects to consume cash until products are commercialised. The Company's shares are traded on the London, New York and Tel Aviv Stock Exchange. Develops therapeutics for the treatment of neurophatic pain and Hepatitis C

Xtrana, Inc.. The Company's principal activity is to seek for the merger options. Earlier the Company's activity was to develop and market nucleic acid-based tests for use in drug discovery, detection of environmental and food contaminants, forensics and identity testing, human and animal diseases, genetic predisposition to disease and other applications. On 26-Jan-2004 the Company sold its intellectual property and is currently seeking a merger candidate. Sold all intellectual properties and currently seeking for merger options

Y.S.P. Southeast Asia Holdings Bhd. The Group's principal activities are the manufacture and trading of pharmaceutical, veterinary, pharmaceutical fine chemicals and other related products. Other activities include provision of management services and investment holding. Its operations are carried out in Malaysia, Philippines, Myanmar, Singapore, Vietnam, Cambodia and Indonesia.

Yuki Gosei Kogyo Co., Ltd.. The Company's principal activities are the manufacturing of pharmaceutical products, industrial organic chemicals and food additives. The Company is also involved in the manufacture and wholesale of tobacco fragrances and related materials. The operations are carried out through the following divisions: Tobacco fragrances and related materials; Pharmaceuticals; Food addictives and Industrial Chemicals and others. Industrial chemicals accounted for 46% of fiscal 2006 revenues; pharmaceuticals, 34%; food additive, 16% & tobacco fragrance, 4%

Yunnan Baiyao Group Co., Ltd.. The Group's principal activities are research, development, manufacture and sale of traditional Chinese medicines and medicinal materials, chemical raw material medicines, organic goods, health care products, cosmetics and beverages. Other activities include operation of hotel and malls; wholesale and retail of externally bought medicines; provision of consulting services; administration of property and sale of cigarettes, liquors, candies, tea, building materials and decoration materials. Its major medicine products are the Yunnan Baiyao series and the Tianqi se

Zenith Laboratories Inc, manufactures, markets and distributes oral solid pharmaceuticals which are identified and sold under their generic names at affordable prices. The drugs are distributed through drug wholesalers and warehousing drug chains to independent retail and chain pharmacies, hospitals, nursing homes and government agencies. The company manufactures 38 drugs which are sold in 71 dosage strengths in tablet and capsule form. The company sells the drugs for use by consumers on doctors' prescriptions. These drugs include drugs for the treatment of endocrine disorders, cardiovascular

Zentiva N.V.. The Group's principal activities are the production of a range of branded generic pharmaceuticals, health care products & cosmetics. In addition, the Group is also involved in the manufacturing of special pharmaceutical equipment & machinery, and also produces packaging materials used in the pharmaceutical industry. The Group's main operations are based in Czech Republic, Slovak Republic, Russia, Poland and Others. Sicomed S.A. was acquired in the year 2005. Slovakofarma s.r.o. was liquidated during the year 2005. Pharmaceutical Prescription accounted for 74% of 2005 revenues; He

Zhejiang Conba Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Research, Development And Sale of Cardia Brain Blood Vessel Medicine And Other.

Zhejiang Huahai Pharmaceutical. The Group's Principal Activities Are The Research, Development, Manufacture And Sale of Pharmaceutical Products. Main Products Include Intermediates, Medicines in The Form of Capsule And Tablets, Captopril, Ketotifen Fumara

Zhejiang Jingxin Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Production And Sale of Resist Infect Medicine And Heart And Brain Blood Vessel Series Medicine.

Zhejiang Medicine Co., Ltd.. The Group's Principal Activities Are Developing, Manufacturing And Distributing Chemical Raw Materials, Chemical Preparation And Medicine in The Form of Tablets, Capsule, Injection And Liquids, to be Taken Orally. It Also Dist

Zhuzhou Qianjin Pharmaceutical Co., Ltd.. The Group's Principal Activities Are The Manufacture And Sale of Tablets, Medical Pills, Syrup And Capsule. Its Products Are Fuke Qianjin Pian, Shujian Fengshi Wine, Buxueyimu Granule, Haoshencai Oral-Take Liquid,

PHARMACEUTICALS FOR VASCULAR DISEASES ACCOUNTED FOR 90 REVENUES; ALSO DERMATOLOGY, OPHTHALMOLOGY, & OTHER THERAPEITOC SECTORS.